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A B S T R A C T
Background
Gonadotropins are the most commonly used medications for controlled ovarian stimulation in in vitro fertilisation (IVF). However,
they are expensive and invasive, and are associated with the risk of ovarian hyperstimulation syndrome (OHSS). Recent calls for more
patient-friendly regimens have led to growing interest in the use of clomiphene citrate (CC) and aromatase inhibitors with or without
gonadotropins to reduce the burden of hormonal injections. It is currently unknown whether regimens using CC or aromatase inhibitors
such as letrozole (Ltz) are as effective as gonadotropins alone.
Objectives
To determine the effectiveness and safety of regimens including oral induction medication (such as clomiphene citrate or letrozole)
versus gonadotropin-only regimens for controlled ovarian stimulation in IVF or intracytoplasmic sperm injection (ICSI) treatment.
Search methods
We searched the following databases: Cochrane Gynaecology and Fertility Group Specialised Register (searched January 2017), the
Cochrane Central Register of Controlled Trials (CENTRAL CRSO), MEDLINE (1946 to January 2017), Embase (1980 to January
2017), and reference lists of relevant articles. We also searched trials registries ClinicalTrials.gov (clinicaltrials.gov/) and the World
HealthOrganization International Clinical Trials Registry Platform (www.who.int/trialsearch/Default.aspx).We handsearched relevant
conference proceedings.
Selection criteria
We included randomized controlled trials (RCTs). The primary outcomes were live-birth rate (LBR) and OHSS.
Data collection and analysis
Three review authors independently assessed trial eligibility and risk of bias. We calculated risk ratios (RR) and Peto odds ratio (OR)
with 95% confidence intervals (CIs) for dichotomous outcomes and mean differences (MD) for continuous outcomes. We analyzed
the general population of women undergoing IVF treatment and (as a separate analysis) women identified as poor responders. We
assessed the overall quality of the evidence using the GRADE approach.
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Main results
We included 27 studies in the updated review. Most of the new trials in the updated review included poor responders and evaluated
Ltz protocols. We could perform meta-analysis with data from 22 studies including a total of 3599 participants. The quality of the
evidence for different comparisons ranged from low to moderate. The main limitations in the quality of the evidence were risk of bias
associated with poor reporting of study methods, and imprecision.
In the general population of women undergoing IVF, it is unclear whether CC or Ltz used with or without gonadotropins compared
to use of gonadotropins along with gonadotropin-releasing hormone (GnRH) agonists or antagonists resulted in a difference in live
birth (RR 0.92, 95% CI 0.66 to 1.27, 4 RCTs, n = 493, I2 = 0%, low-quality evidence) or clinical pregnancy rate (RR 1.00, 95% CI
0.86 to 1.16, 12 RCTs, n = 1998, I2 = 3%, moderate-quality evidence). This means that for a typical clinic with 23% LBR using a
GnRH agonist regimen, switching to CC or Ltz protocols would be expected to result in LBRs between 15% and 30%. Clomiphene
citrate or Ltz protocols were associated with a reduction in the incidence of OHSS (Peto OR 0.21, 95% CI 0.11 to 0.41, 5 RCTs, n
= 1067, I2 = 0%, low-quality evidence). This means that for a typical clinic with 6% prevalence of OHSS associated with a GnRH
regimen, switching to CC or Ltz protocols would be expected to reduce the incidence to between 0.5% and 2.5%. We found evidence
of an increase in cycle cancellation rate with the CC protocol compared to gonadotropins in GnRH protocols (RR 1.87, 95% CI 1.43
to 2.45, 9 RCTs, n = 1784, I2 = 61%, low-quality evidence). There was moderate quality evidence of a decrease in the mean number
of ampoules used,) and mean number of oocytes collected with CC with or without gonadotropins compared to the gonadotropins in
GnRH agonist protocols, though data were too heterogeneous to pool.
Similarly, in the poor-responder population, it is unclear whether there was any difference in rates of live birth (RR 1.16, 95% CI 0.49
to 2.79, 2 RCTs, n = 357, I2 = 38%, low-quality evidence) or clinical pregnancy (RR 0.85, 95% CI 0.64 to 1.12, 8 RCTs, n = 1462,
I2 = 0%, low-quality evidence) following CC or Ltz with or without gonadotropin versus gonadotropin and GnRH protocol. This
means that for a typical clinic with a 5% LBR in the poor responders using a GnRH protocol, switching to CC or Ltz protocols would
be expected to yield LBRs between 2% to 14%. There was low quality evidence that the CC or Ltz protocols were associated with an
increase in the cycle cancellation rate (RR 1.46, 95% CI 1.18 to 1.81, 10 RCTs, n = 1601, I2 = 64%) and moderate quality evidence
of a decrease in the mean number of gonadotropin ampoules used and the mean number of oocytes collected, though data were too
heterogeneous to pool. The adverse effects of these protocols were poorly reported. In addition, data on foetal abnormalities following
use of CC or Ltz protocols are lacking.
Authors’ conclusions
We found no conclusive evidence indicating that clomiphene citrate or letrozole with or without gonadotropins differed from go-
nadotropins in GnRH agonist or antagonist protocols with respect to their effects on live-birth or pregnancy rates, either in the general
population of women undergoing IVF treatment or in women who were poor responders. Use of clomiphene or letrozole led to a
reduction in the amount of gonadotropins required and the incidence of OHSS. However, use of clomiphene citrate or letrozole may
be associated with a significant increase in the incidence of cycle cancellations, as well as reductions in the mean number of oocytes
retrieved in both the general IVF population and the poor responders. Larger, high-quality randomized trials are needed to reach a firm
conclusion before they are adopted into routine clinical practice.
P L A I N L A N G U A G E S U M M A R Y
Use of clomiphene citrate or letrozole in in vitro fertilisation treatment
Review question
The aim of this review was to compare treatment with clomiphene citrate (CC) or letrozole (Ltz) versus gonadotropins alone for
stimulation of the ovaries during in vitro fertilisation (IVF) treatment.
Background
Gonadotropin hormonal injections are commonly used in an IVF treatment to stimulate the ovaries to produce eggs, which can then be
mixed with sperm in the laboratory to create embryos for transfer into the uterus. However, these injections are expensive, inconvenient,
and are associated with side effects. Calls for patient-friendly stimulation regimens have led to the use of tablets such as clomiphene or
letrozole instead of injections, but it is unclear whether these are associated with similar pregnancy rates.
Study characteristics
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We included 27 studies, of which 22 studies with a total of 3599 participants had data suitable for analysis. We studied the general IVF
population and those women who had fewer eggs (poor responders) during IVF separately. This is an update of a previous Cochrane
Review first published in 2012. The evidence is current to 10 January 2017.
Key results
There was no clear evidence of a difference in live-birth or pregnancy rates between the groups in the general IVF population. Low-
quality evidence suggests that for a typical clinic with 23% live-birth rate (LBR) using only gonadotropin hormonal injections, switching
to CC or Ltz regimens would be expected to result in LBRs between 15% and 30%.
The risk of ovarian hyperstimulation syndrome (OHSS) was lower with CC or Ltz use compared to gonadotropins alone. Low-quality
evidence suggests that for a typical clinic with 6% prevalence of OHSS associated with a gonadotropin hormonal injection, switching
to CC or Ltz regimen would be expected to reduce the incidence to between 0.5% and 2.5%.
Among women designated as poor responders, there was no clear evidence of a difference between the groups in live-birth or pregnancy
rates. Low-quality evidence suggests that for a typical clinic with 5% LBRs in poor responders using only gonadotropin hormonal
injection, switching to CC or Ltz regimen would be expected to result in LBRs between 2% and 14%. The side effects of these drugs
and data on foetal abnormalities following CC or Ltz protocols were poorly reported.
Quality of the evidence
The quality of the evidence for the different comparisons ranged from low tomoderate. The main limitations were risk of bias associated
with poor reporting of study methods, and imprecision.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Clomiphene citrate or letrozole with or without gonadotropins (with or without midcycle antagonist) compared to gonadotropins (with GnRH agonists or midcycle antagonist)
in IVF and ICSI cycles in general population for controlled ovarian stimulation
Patient or population: Women undergoing controlled ovarian st imulat ion in IVF and ICSI cycles (general populat ion)
Setting: Assisted reproduct ion clinic
Intervention: Clomiphene citrate or letrozole with or without gonadotropins (with or without m idcycle antagonist)
Comparison: Gonadotropins (with GnRH agonists or midcycle antagonist)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with
gonadotropins (with
GnRH agonists or mid-
cycle antagonist)
Risk with clomiphene
citrate or letrozole
with or without go-
nadotropins (with or
without midcycle an-
tagonist)
Live birth per woman 235 per 1000 216 per 1000
(155 to 299)
RR 0.92
(0.66 to 1.27)
493
(4 RCTs)
⊕⊕©©
LOW1,2
Ovarian hyperstimula-
tion syndrome per
woman
63 per 1000 14 per 1000
(7 to 27)
Peto OR 0.21
(0.11 to 0.41)
1067
(5 RCTs)
⊕⊕©©
LOW1,3
Clinical pregnancy rate
per woman
248 per 1000 248 per 1000
(213 to 288)
RR 1.00
(0.86 to 1.16)
1998
(12 RCTs)
⊕⊕⊕©
MODERATE1
Cancellation rate per
woman
80 per 1000 150 per 1000
(114 to 196)
RR 1.87
(1.43 to 2.45)
1784
(9 RCTs)
⊕⊕©©
LOW1,4
Mean number of go-
nadotropin ampoules
used per woman
The mean number of
ampoules used in the
control group ranged
f rom 18 to 50
In all studies CC plus
gonadotropins was as-
sociated with use
of fewer ampoules.
The mean dif ference
- 1098
(6 RCTs)
⊕⊕⊕©
MODERATE1,5
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ranged f rom 5.6 to 24.
6 ampoules
Mean
number of oocytes re-
trieved per woman
The mean number of
oocytes retrieved in the
control group ranged
f rom 5 to 17
In seven studies
CC plus gonadotropins
was associated with re-
trieval of fewer oocytes,
with the mean dif fer-
ence ranging f rom 1.
02 to 6.20 oocytes.
The dif ference was sta-
t ist ically signif icant in
f ive of these studies.
The eighth study found
no evidence of a dif -
ference between the
groups
- 1481
(8 RCTs)
⊕⊕⊕©
MODERATE1,5
*The risk in the intervention group (and its 95% conf idence interval) is based on the mean risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; GnRH: gonadotropin-releasing hormone; ICSI: intracytoplasmic sperm inject ion; IVF: in vit ro fert ilisat ion; MD: mean dif ference; OR: odds rat io; RCT:
randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of the ef fect
1Downgraded one level (serious risk of bias). All included studies had unclear risk of bias for allocat ion concealment.
2Downgraded one level (serious imprecision). Conf idence interval is wide and compatible with benef it in either group, or with
no ef fect.
3Downgraded one level (serious imprecision). Small number of events.
4Downgraded one level (serious inconsistency). I2 61%.
5Not downgraded for inconsistency. Although there was signif icant stat ist ical heterogeneity, this referred to the magnitude
of dif f erence rather than direct ion of evidence.5
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B A C K G R O U N D
Description of the condition
Controlled ovarian stimulation (COS) is an essential step in in
vitro fertilisation (IVF) treatment (Arslan 2005). The goal of COS
is to encourage the recruitment of a larger number of oocytes and
hencemaximise the number of dominant follicles that are available
for retrieval (Strickler 1995). A number of different hormones,
used within a variety of protocols, have been described for COS
in IVF (Balasch 2001; Gregoriou 2008; Khalaf 2002; Kingsland
1992; Out 2000;Weigert 2002). Conventional regimens for ovar-
ian stimulation are based on gonadotropins alone and are complex
and expensive. In addition, they are associatedwith the risk of com-
plications such as ovarian hyperstimulation syndrome and multi-
ple pregnancies (Fauser 1999; Olivennes 1998; Verberg 2009).
Description of the intervention
Administered initially on its own (Trounson 1981), and then later
in conjunction with gonadotropins (Lopata 1983; Quigley 1983),
clomiphene citrate (CC) was the first drug to be used for COS in
IVF (Marrs 1984). Concerns about anti-oestrogenic side effects on
the whole reproductive tract, Eden 1989, Kokko 1981, Nakamura
1997, Rogers 1991, Yagel 1992, and premature luteinising hor-
mone surge with subsequent premature ovulation and luteinisa-
tion as well as poor follicular development, Abdalla 1990,Messinis
1985, have led to a search for alternative strategies. Aromatase in-
hibitors have emerged as an alternative to CC as an oral ovulation
induction drug (Holzer 2006). The combining of the aromatase
inhibitor letrozole (Ltz) with gonadotropin during COS has been
suggested as away to reduce the total gonadotropin requirement in
IVF (Goswami 2004). Gonadotropin-releasing hormone (GnRH)
agonists were introduced into clinical practice for pituitary down-
regulation in order to achieve better control of ovarian stimula-
tion and timing of ovulation (Porter 1984). Long protocol GnRH
agonist pituitary downregulation followed by administration of
gonadotropins became the norm. A number of reports suggested
that its use resulted in improved follicular development, lower
rates of cycle cancellation, and higher rates of fertilisation and
implantation (Abdalla 1990; Macnamee 1989; Smitz 1987), as
well as significantly better IVF outcomes (Hughes 1992). Later,
GnRH antagonists were introduced for pituitary control. Most
conventional stimulation regimens now use either GnRH agonists
or antagonists along with gonadotropins. In recent years, the use
of CC or Ltz along with gonadotropins has grown, particularly in
women expected to respond poorly to controlled ovarian hyper-
stimulation (Goswami 2004; Lee 2012; Ragni 2012).
How the intervention might work
Clomiphene citrate has both oestrogenic and anti-oestrogenic ef-
fects (Glasier 1989). It acts primarily by occupying the hypothala-
mic oestrogen receptors for a longer period than oestrogens (weeks
versus hours) (Mikkelson 1986). Consequently, it increases the
release of GnRH through a negative feedback mechanism, with
an ultimate increase in follicle-stimulating hormone and lutein-
ising hormone (Dickey 1996). This increase in endogenous go-
nadotropin levels stimulates the ovaries and increases the number
of follicles reaching ovulation (Kousta 1997). A selective aromatase
inhibitor such as letrozole acts by preventing conversion of andro-
gens to oestrogens in the ovary, thus releasing the hypothalamo-
pituitary axis from the negative feedback of oestrogen. This results
in an increase in follicle-stimulating hormone secretion, eventu-
ally leading to follicular development (Holzer 2006)
Why it is important to do this review
Calls for milder forms of ovarian stimulation in IVF have led to
a revival of the use of CC (Edwards 1996). It has been suggested
that the use of CC, alone or in combination with other drugs, is
consistent with the concept of ’patient-friendly IVF’ (Engel 2002;
Ingerslev 2001), as it is inexpensive, readily available, safe, and
can be administered orally (Lehmann 1988; Quigley 1983; Ronen
1988). The concept of patient-friendly IVF involves the use of
natural cycle IVF, low-dose gonadotropins, or oral ovulation in-
duction medications such as CC or aromatase inhibitors alone or
with gonadotropins (Fauser 1999; Ingerslev 2001). While the ef-
fects of adding GnRH agonists or antagonists to gonadotropins
compared to gonadotropins alone have been examined in previous
systematic reviews (Al-Inany 2016; Hughes 1992), reports on the
effectiveness of CC and gonadotropins compared to standard long
or short protocols have demonstrated conflicting results (Dhont
1995; Grochowski 1999;Weigert 2002). Hence we decided to un-
dertake this systematic review of randomized trials to investigate
the effectiveness of oral ovulation induction medications along
with gonadotropins versus gonadotropins alone (with GnRH ag-
onists or antagonists) in controlled ovarian stimulation for IVF or
intracytoplasmic sperm injection (ICSI) treatments.
O B J E C T I V E S
To determine the effectiveness and safety of regimens including
oral inductionmedication (such as clomiphene citrate or letrozole)
versus gonadotropin-only regimens for controlled ovarian stimu-
lation in IVF or ICSI treatment.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We included parallel-group randomized controlled trials (RCTs)
if they compared oral ovarian stimulation agents, alone or in com-
bination with gonadotropins, versus conventional gonadotropin
(with GnRH agonist or antagonist) protocols in women under-
going IVF or ICSI. We excluded cross-over trials and quasi-ran-
domised trials.
Types of participants
Women who were subfertile and undergoing fresh IVF or ICSI
were eligible for inclusion.
Types of interventions
Interventions
• Clomiphene citrate with or without gonadotropins
• Aromatase inhibitors with or without gonadotropins
• Other oral induction medications with or without
gonadotropins
Control
• Gonadotropins
Types of outcome measures
All outcome measures were expressed as per woman.
Primary outcomes
1. Live-birth rate per woman randomized, defined as delivery
of a live foetus after 20 completed weeks of gestation
2. Ovarian hyperstimulation syndrome (OHSS) for the
general IVF population only
Secondary outcomes
1. Ongoing pregnancy rate, defined as evidence of a
gestational sac with foetal heart motion at 12 weeks confirmed
with ultrasound
2. Clinical pregnancy rate, defined as evidence of a gestational
sac confirmed with ultrasound
3. Cycle cancellation rate
4. Mean number of ampoules of gonadotropin used
5. Mean number of oocytes retrieved
6. Multiple pregnancy rate
7. Rate of miscarriage, defined as foetal loss after confirmation
of a gestational sac confirmed on ultrasound, and up to 20
completed weeks of gestation
8. Rate of ectopic pregnancies
9. Rate of foetal abnormalities
Search methods for identification of studies
We sought all published and unpublished RCTs comparing oral
ovulation induction medications alone or in combination with go-
nadotropins versus conventional gonadotropin (with GnRH ago-
nist or antagonist) protocols in women undergoing IVF or ICSI.
We used the following search strategy without language restric-
tions and in consultation with the Cochrane Gynaecology and
Fertility Group Information Specialist.
Electronic searches
We performed an updated search of the following electronic
databases, trials registers, and websites ( from inception to 10
January 2017): Cochrane Gynaecology and Fertility Group Spe-
cialised Register (Appendix 1), Cochrane Central Register of Con-
trolledTrials (CENTRALCRSO) (Appendix 2),MEDLINE (Ap-
pendix 3), Embase (Appendix 4), PsycINFO (Appendix 5), and
CINAHL (Cumulative Index to Nursing and Allied Health Lit-
erature) (Appendix 6). We combined the MEDLINE search with
the Cochrane Highly Sensitive Search Strategy for identifying ran-
domized trials, as described inChapter 6 of theCochrane Handbook
for Systematic Reviews of Interventions (Lefebvre 2011). We com-
bined the Embase search with trial filters developed by the Scot-
tish Intercollegiate Guidelines Network (SIGN) (www.sign.ac.uk/
search-filters.html).
Other electronic sources of trials included registers for on-
going and registered trials: ClinicalTrials.gov, a service of the
US National Institutes of Health (clinicaltrials.gov/) and the
World Health Organization International Clinical Trials Reg-
istry Platform (www.who.int/trialsearch/Default.aspx) (Appendix
7); conference abstracts in the Clarivate analytics Web of
Science (www.wokinfo.com); LILACS (Latin American and
Caribbean Health Sciences Literature) database as a source of
Portuguese and Spanish trials (lilacs.bvsalud.org/en/); PubMed (
www.ncbi.nlm.nih.gov/pubmed/), where the random control fil-
ter for PubMed was taken from Chapter 6 of the Cochrane Hand-
book for Systematic Reviews of Interventions; and the OpenGrey
database (www.opengrey.eu/) and Google for grey literature. We
also searched PubMed and Google in order to find any published
trials not yet indexed in the major databases .
Searching other resources
We handsearched the reference lists of articles retrieved by the
search. Any relevant journals and conference abstracts that were
not covered in the Cochrane Gynaecology and Fertility Group
Specialised Register were handsearched in liaison with the Infor-
mation Specialist.
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Data collection and analysis
We conducted data collection and analysis in accordance with the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).
Selection of studies
Three review authors (AG, MSK, KY) scanned the titles and ab-
stracts of articles retrieved by the updated search, removing those
that were clearly irrelevant. We retrieved the full text of all po-
tentially eligible studies. Three review authors (KY, AG, MSK)
independently examined the full-text articles for compliance with
the inclusion criteria and selected those studies that were eligible
for inclusion in the review. Where required we corresponded with
study investigators to clarify study eligibility (e.g. with respect to
participant eligibility criteria and allocation methods). Disagree-
ments as to study eligibility were resolved by consensus or by dis-
cussion with a fourth review author (AM).
Data extraction and management
We entered study details into the ’Characteristics of included stud-
ies’ table using ReviewManager software (RevMan 2014) and col-
lected outcome data.
We extracted the following information from the included studies.
Trial methods
• Method of randomization.
• Method of allocation concealment.
• Exclusion of participants after randomization, proportion
of and reasons for losses at follow-up.
• Duration, timing, and location of the trial (single-centre or
multicentre trial), duration of follow-up.
• Co-interventions.
• The presence of a power calculation.
Participants
• Cause and duration of pre-existing infertility.
• Age of the women and parity.
• Investigative work-up.
• Previously administered treatment(s).
Intervention
• Type of intervention and control comparator.
• Dose and type of regimen for controlled ovarian
stimulation.
• We differentiated between whether the study population
included all women undergoing assisted reproductive technology
or if it was limited to women who had responded poorly in a
previous attempt or were expected to have a diminished response.
Outcomes
• Outcomes reported.
• How outcomes were defined.
• Timing of outcome measurement.
We extracted data were extracted from eligible studies using a data
extraction form designed and pilot-tested by the authors. Where
studies had multiple publications, we used the main trial report as
the reference and supplemented additional details from secondary
papers. Review authors corresponded with study investigators in
order to resolve any data queries, as required. Three review au-
thors (AG, MSK, KYKY) independently extracted the data. Any
disagreements between these review authors were resolved by a
fourth review author (SB).
Assessment of risk of bias in included studies
We assessed and reported on the risk of bias of included studies
in accordance with the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011), which recommends the explicit
reporting of the following domains.
Sequence generation
Was sequence generation at low risk of bias (e.g. use of a ran-
dom number table, a computer random number generator, or coin
tossing), or unclear risk of bias (insufficient information provided
about the process of sequence generation)?
Allocation concealment
Was allocation concealment at low risk of bias (e.g. use of central
allocation or opaque, sealed envelopes), high risk of bias (e.g. use
of an open random allocation schedule), or unclear risk of bias
(insufficient information provided about the process of allocation
concealment)?
Blinding of participants and assessors
There were two comparisons in this review. For the general IVF
population, we considered lack of blinding as high risk since as-
sessment of one of the primary outcomes (OHSS) may be subject
to bias. For the poor responder population, the primary outcome
(live birth) was objective, therefore we judged studies evaluating
the poor responder population without use of blinding as low risk
as it was not likely to influence the outcome.
Selective outcome reporting
Was the study free of selective reporting, that is at low risk of bias
(e.g. the study protocol was available and all prespecified outcomes
had been reported on, or the study protocol was not available but
all prespecified outcomes had been reported); high risk of bias
(e.g. not all prespecified primary outcomes had been reported); or
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unclear risk of bias (insufficient information provided about the
process of outcome reporting)? We tried to ascertain the risk of
within-study reporting bias by seeking protocols for the original
studies and checking whether the planned outcomes had been
reported.
Other sources of bias
Other problems that could put a trial at high risk of bias include
differences at baseline between study groups.
Two review authors (AG, MSK) assessed these domains, resolving
any disagreements by consensus or by discussion with a third re-
view author (AM). We presented the conclusions in the ’Risk of
bias’ table and incorporated them into the interpretation of the re-
view findings. Where included studies failed to report the primary
outcome of live birth, but did report interim outcomes such as
pregnancy, we undertook informal assessment as to whether those
studies reporting the primary outcome have similar values as the
interim outcomes.
We presented the ’Risk of bias’ assessment in the ’Characteristics
of included studies’ table, including commentary about each of
the domains. This led to an overall assessment of the risk of bias
of included studies.
Measures of treatment effect
For dichotomous data (e.g. live-birth rates), we used the numbers
of events in the control and intervention groups of each study
to calculate risk ratios (RR). Where events were very rare, we
calculated the Peto odds ratio (OR). For continuous data (e.g.
mean number of retrieved oocytes), we calculated mean differ-
ences (MD) between treatment groups. We presented the 95%
confidence intervals (CI) for all outcomes.
Unit of analysis issues
We pooled data that reported outcomes per woman randomized
wherever possible.
Dealing with missing data
In the case of missing data in the included studies, we contacted
the original investigators by email or post to request the relevant
missing information. We reported the data according to the inten-
tion-to-treat principle wherever possible. We assumed live births
not to have occurred in participants without a reported outcome.
For other outcomes (e.g number of oocytes retrieved and ampoules
of gonadotropins used), we only analyzed the available data.
Assessment of heterogeneity
We judged whether the clinical andmethodological characteristics
of the included studies were sufficiently similar for meta-analysis
to provide a meaningful summary. We assessed statistical hetero-
geneity by using theChi2 test. A low P value (or a large Chi2 statis-
tic relative to its degree of freedom) potentially provides evidence
of heterogeneity of intervention effects and shows that results are
not influenced by chance alone (Higgins 2011). We also used the
I2 statistic to assess the impact of the heterogeneity on the meta-
analysis. We took an I2 greater than 50% to indicate substantial
heterogeneity.
Assessment of reporting biases
In view of the difficulty in detecting and correcting for publication
bias andother reporting biases, we tried tominimise their potential
impact by ensuring a comprehensive search for eligible studies
and by being alert to duplication of data. Whenever there was an
adequate number of studies in an analysis, we used a funnel plot to
explore whether a difference was due to publication or reporting
bias.
Data synthesis
If studies were sufficiently similar, we performed meta-analysis
whenever there were at least two trials assessing the same outcome.
We performed statistical analysis in accordance with the guidelines
for statistical analysis in Chapter 9 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We combined
the data from primary studies using a fixed-effect model, unless
heterogeneity was considerable (I2 > 50%), inwhich case we used a
random-effects model. This applied to the following comparisons.
1. Clomiphene citrate or letrozole with or without
gonadotropins in conjunction with or without midcycle GnRH
antagonist versus gonadotropins (with GnRH agonist or
midcycle antagonist protocols) in IVF and ICSI cycles in the
general population.
2. Clomiphene citrate or letrozole with or without
gonadotropins in conjunction with or without midcycle GnRH
antagonist versus gonadotropins (with GnRH agonist or
midcycle antagonist protocols) in IVF and ICSI cycles in a
population of poor responders.
An increase in the risk of a particular outcome, which may be ben-
eficial (e.g. live birth) or detrimental (e.g. OHSS), was displayed
graphically in the meta-analyses to the right of the centre line, and
a decrease in the risk of an outcome was displayed to the left of
the centre line.
Subgroup analysis and investigation of heterogeneity
We planned to the following subgroup analyses.
• Clomiphene citrate with or without gonadotropins in
conjunction with or without antagonist versus GnRH agonist
protocol.
• Clomiphene citrate with or without gonadotropins in
conjunction with or without antagonist versus GnRH antagonist
protocol.
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• Letrozole with or without gonadotropins in conjunction
with or without antagonist versus GnRH agonist protocol.
• Letrozole with or without gonadotropins in conjunction
with or without antagonist versus GnRH antagonist protocol.
Sensitivity analysis
We conducted sensitivity analysis for primary outcomes (live birth
and OHSS) to determine whether the conclusions were robust to
decisions made during the review process. These analyses included
consideration of whether the review conclusions would have dif-
fered if:
1. eligibility was restricted to studies without high risk of bias
(not at high risk of bias in any domain and at low risk for
randomization procedures);
2. a random-effects model had been adopted;
3. the summary effect measure was odds ratio (OR) rather
than risk ratio (RR) and vice versa.
Overall quality of the body of evidence: ’Summary of
findings’ tables
We used the GRADE approach to summarise and interpret find-
ings (Schünemann 2011), and GRADEpro GDT 2015 software
to import data from RevMan 2014 to create ’Summary of find-
ings’ tables. These tables provide outcome-specific information
concerning within-study risk of bias (methodological quality), di-
rectness of evidence, heterogeneity, precision of effect estimates,
and risk of publication bias, and the sum of available data on all
outcomes rated as important to patient care and decision-making.
The GRADE approach specifies four levels of quality, as follows.
• High quality: Further research is very unlikely to change
our confidence in the estimate of effect.
• Moderate quality: Further research is likely to have an
important impact on our confidence in the estimate of effect and
may change the estimate.
• Low quality: Further research is very likely to have an
important impact on our confidence in the estimate of effect and
is likely to change the estimate.
• Very low quality: We are very uncertain about the estimate.
Two review authors independently assessed the quality of the evi-
dence, resolving any disagreements by discussion.
The main comparisons were: CC or Ltz with or without go-
nadotropins (with or without midcycle GnRH antagonist) versus
gonadotropins (with GnRH agonist or midcycle antagonist pro-
tocols) in IVF and ICSI cycles in the general population and in
poor responders. We presented ’Summary of findings’ tables for
the two comparisons separately.
We included the following outcomes in the ’Summary of findings’
tables.
1. Live-birth rate
2. Ovarian hyperstimulation syndrome for the general IVF
population only
3. Clinical pregnancy rate
4. Cycle cancellation rate
5. Mean number of ampoules of gonadotropin used
6. Mean number of oocytes retrieved.
R E S U L T S
Description of studies
Results of the search
The original search strategy identified 61 records through database
searching. We identified one additional record as an abstract for
an ongoing trial through our search of registered trials (Youssef
2011); we contacted the corresponding author by email for more
information and obtained some of the missing data. Of the 62
studies identified, five duplicateswere removed, leaving 57 records.
We excluded abstracts if a full article was detected for the same
study, and excluded 30 abstracts that did not meet the basic inclu-
sion criteria as identified from the study title and abstract. Where
the title or abstract identified a study as ’possibly for inclusion’,
or if there was any doubt about the exclusion of a study, we ob-
tained the full article for further evaluation. Of the remaining 27
studies identified as possibly for inclusion (Abdalla 1990; Ashrafi
2005; Cassidenti 1992; Dhont 1995; Engel 2002; Fenichel 1988;
Ferrier 1990; Fiedler 2001; Ghosh Dastidar 2010; Gonen 1990;
Grochowski 1999;Harrison 1994; Imoedemhe 1987; Jutras 1991;
Karimzadeh 2010; Karimzadeh 2011; Kingsland 1992; Kubik
1990; Lin 2006; Long 1995; Macnamee 1989; Martinez 2003;
Quigley 1984; Shelton 1991; Tummon 1992; Weigert 2002;
Youssef 2011), 14 studies were eligible for inclusion in the fi-
nal analysis of the original review (Ashrafi 2005; Fenichel 1988;
Fiedler 2001; Ghosh Dastidar 2010; Grochowski 1999; Harrison
1994; Jutras 1991; Karimzadeh 2010; Kingsland 1992; Lin 2006;
Long 1995; Tummon 1992; Weigert 2002; Youssef 2011).
The targeted update search resulted in 191 records. Three review
authors independently examined the titles and abstracts, identify-
ing 43 records as potentially eligible, for which full papers were ob-
tained. We excluded 27 full texts (Ferraretti 2015; Ghanem 2013;
Goldman 2014; Ibrahim 2012; Kim 2000; Legro 2012; Liu 2016;
Nagulapally 2012; Nahid 2012; Nakajo 2011; NCT01577199;
NCT01577472; NCT01679574; NCT01718444;
NCT01791751; NCT01856062; NIH/NICHD Reproductive
Medicine Network 2013; Oktem 2015; Oride 2015; Reindollar
2011; Rose 2015; Roy 2012; Sharma 2014; Siristatidis 2016;
Wagman 2010; Ye 2016; Zhang 2014), and included 14 new
studies (15 articles; one study had a companion paper) (Bastu
2016; Elnashar 2016; Fujimoto 2014;Galal 2012;Goswami 2004;
Jindal 2013; Lee 2012; Mohsen 2013; Mukherjee 2012; Nabati
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2016; Pilehvari 2016; Ragni 2012; Revelli 2014; Schimberni
2016). In addition, we identified a companion paper to one
of the already included studies (Youssef 2011), but it did
not provide any new data. We identified three ongoing stud-
ies (NCT 01921166; NCT 01948804; NCT 02237755). See
Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification; and
Characteristics of ongoing studies for further details.
We excluded a trial that was included in original review (Fiedler
2001), since both groups included clomiphene citrate (CC) and
gonadotropins. The final number of studies included in the up-
dated review was 27 (13 studies from original review and 14 new
studies from the updated search). The search result is summarized
in the PRISMA figure (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
See Characteristics of included studies for details.
Design
Our update includes 13 RCTs that were included in the origi-
nal review (Ashrafi 2005; Fenichel 1988; Ghosh Dastidar 2010;
Grochowski 1999;Harrison 1994; Jutras 1991;Karimzadeh 2010;
Kingsland 1992; Lin 2006; Long 1995; Tummon 1992; Weigert
2002; Youssef 2011). None were multicentred. Three studies re-
ported an a priori power calculation (Grochowski 1999; Lin 2006;
Tummon 1992). None of the included trials reported financial
support by any pharmaceutical company.
Following the updated search, we included 14 more RCTs in the
current review (Bastu 2016; Elnashar 2016; Fujimoto 2014; Galal
2012; Ghosh Dastidar 2010; Jindal 2013; Lee 2012; Mohsen
2013;Mukherjee 2012;Nabati 2016; Pilehvari 2016; Ragni 2012;
Revelli 2014; Schimberni 2016). All trials were single-centre tri-
als, and none received financial support from any pharmaceutical
company.
Participants
All of the included studies involved subfertile couples undergoing
IVF treatment, but the inclusion criteria differed among the stud-
ies (Table 1). One study did not mention the total number of par-
ticipants (Jutras 1991), and one study did not mention the num-
ber of participants allocated to each interventional arm (Ghosh
Dastidar 2010).
We separated the trials that included the general IVF population
(15 trials), Elnashar 2016, Fenichel 1988, Ghosh Dastidar 2010,
Galal 2012, Grochowski 1999, Harrison 1994, Jindal 2013, Jutras
1991, Karimzadeh 2010, Kingsland 1992, Lin 2006, Long 1995,
Mukherjee 2012, Tummon 1992, Weigert 2002, from those that
included poor responders (12 trials) (Ashrafi 2005; Bastu 2016;
Fujimoto 2014; Goswami 2004; Lee 2012; Mohsen 2013; Nabati
2016; Pilehvari 2016; Ragni 2012; Revelli 2014; Schimberni
2016; Youssef 2011), and evaluated them separately.
Interventions
Cycle characteristics of included studies have been shown in Table
1.
Among the 15 trials evaluating the intervention in the general
population of women undergoing IVF, 11 compared CC with
gonadotropin (with or without antagonist) versus gonadotropin
in short or long protocol (Fenichel 1988; Ghosh Dastidar 2010;
Grochowski 1999;Harrison 1994; Jutras 1991;Karimzadeh 2010;
Kingsland 1992; Lin 2006; Long 1995; Tummon 1992; Weigert
2002). One trial compared letrozole (Ltz) with gonadotropin and
antagonist versus gonadotropin in long protocol (Elnashar 2016).
Two trials compared Ltz with gonadotropin and antagonist ver-
sus gonadotropin in antagonist protocol (Galal 2012; Mukherjee
2012).One trial used bothCCorLtz alongwith gonadotropin and
antagonist versus gonadotropin in long protocol (Jindal 2013).
Among the 12 trials evaluating the intervention in poor respon-
ders, three compared CC with gonadotropin (with or without
antagonist) versus gonadotropin in either short or long protocol
(Ashrafi 2005; Revelli 2014; Youssef 2011). One trial compared
CC versus gonadotropin in short protocol (Ragni 2012). One trial
compared CC along with gonadotropins and an antagonist ver-
sus two comparator arms - short protocol and antagonist protocol
(Schimberni 2016). Two trials compared CC with gonadotropin
(with or without antagonist) versus antagonist protocol (Fujimoto
2014; Pilehvari 2016). The remainingfive trials comparedLtzwith
gonadotropin (with or without antagonist) versus gonadotropin
in agonist protocol, Goswami 2004, Nabati 2016, Mohsen 2013,
and antagonist protocol (Bastu 2016; Lee 2012).
Outcomes
Of the trials involving the general IVF population, four tri-
als reported the primary outcome of live birth (Harrison 1994;
Kingsland 1992; Lin 2006; Long 1995), and five trials reported the
primary outcome of ovarian hyperstimulation syndrome (OHSS)
(Grochowski 1999; Karimzadeh 2010; Lin 2006; Mukherjee
2012; Weigert 2002).
Of the trials on poor responders, three trials reported live-birth rate
(Fujimoto 2014; Lee 2012; Ragni 2012), and one trial reported
cumulative live-birth rate (fresh and frozen cycles) per woman
randomized (Fujimoto 2014).
Excluded studies
A list of excluded studies along with the reasons for their exclu-
sion is provided in the Characteristics of excluded studies table.
We excluded four studies that used quasi-randomisation methods
(Abdalla 1990; Kubik 1990; Macnamee 1989; Siristatidis 2016).
We excluded nine studies that were non-randomised trials (Engel
2002; Ferraretti 2015; Gonen 1990; Kim 2000; Oktem 2015;
Oride 2015; Rose 2015; Sharma 2014; Shelton 1991). We ex-
cluded two studies in which participants may have had either ga-
mete intrafallopian transfer (GIFT) or IVF and it was not possi-
ble to separate the outcomes of the two forms of assisted repro-
duction (Dhont 1995; Ferrier 1990). We excluded one study in
which participants were fertile oocyte donors (Cassidenti 1992).
We excluded eight trials because of an inappropriate comparison
(Fiedler 2001; Goldman 2014; Imoedemhe 1987; Karimzadeh
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2011; Martinez 2003; Nagulapally 2012; Nakajo 2011; Quigley
1984).We excluded seven trials in which participants were not un-
dergoing IVF or ICSI treatment (Ghanem 2013; Ibrahim 2012;
Legro 2012; Nahid 2012; Reindollar 2011; Roy 2012; Wagman
2010). We excluded three trials because participants did not un-
dergo fresh transfers (Liu 2016; Ye 2016; Zhang 2014).
Risk of bias in included studies
We assessed the included studies for methodological quality using
the Cochrane ’Risk of bias’ tool (Higgins 2011). See the ’Risk of
bias’ graph (Figure 2) and ’Risk of bias’ summary (Figure 3).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Generation of random sequence
The method of randomization was computer based in 11 stud-
ies (Bastu 2016; Harrison 1994; Jindal 2013; Karimzadeh 2010;
Lee 2012; Mohsen 2013; Ragni 2012; Revelli 2014; Schimberni
2016; Weigert 2002; Youssef 2011). Two studies employed sim-
ple randomization using a sequence of randomized numbers
(Goswami 2004; Tummon 1992). The method of randomization
was not mentioned in 14 studies (Ashrafi 2005; Elnashar 2016;
Fenichel 1988; Fujimoto 2014;Galal 2012;GhoshDastidar 2010;
Grochowski 1999; Jutras 1991; Kingsland 1992; Lin 2006; Long
1995; Mukherjee 2012; Nabati 2016; Pilehvari 2016). See the
’Risk of bias’ graph (Figure 2) and ’Risk of bias’ summary (Figure
3).
Allocation concealment
Thirteen studies partially described the method of allocation con-
cealment (e.g. “sealed envelope”) and were assessed as at unclear
risk of bias (Ashrafi 2005; Bastu 2016; Elnashar 2016; Goswami
2004; Grochowski 1999; Karimzadeh 2010; Kingsland 1992; Lee
2012; Lin 2006; Mohsen 2013; Mukherjee 2012; Ragni 2012;
Youssef 2011). In one study participant allocation was performed
by an independent second party (Harrison 1994). Twelve studies
did not mention the method of allocation concealment and were
assessed as at unclear risk of bias (Fenichel 1988; Fujimoto 2014;
Galal 2012; Jindal 2013; Jutras 1991; Long 1995; Nabati 2016;
Pilehvari 2016; Schimberni 2016; Tummon 1992;Weigert 2002).
Only one study stated that allocation concealment was done us-
ing consecutively numbered, opaque, sealed envelopes, which we
assessed as at low risk of bias (Figure 2; Figure 3) (Revelli 2014).
Blinding
Most of the included studies did not report blinding of either
clinician or participant. One trial stated that blinding was not
used (Youssef 2011). Two trials described single-blinding of the
clinician to the treatment allocation (Goswami 2004; Harrison
1994), while two other trials described blinding of clinicians and
embryologists to the treatment allocation (Bastu 2016; Nabati
2016).
Incomplete outcome data
We assessed a total of 15 trials as at low risk of attrition bias; the
majority of these reported no loss to follow-up (Goswami 2004;
Grochowski 1999; Harrison 1994; Kingsland 1992; Lee 2012;
Lin 2006; Long 1995; Mohsen 2013; Mukherjee 2012; Pilehvari
2016; Revelli 2014), while the few that had dropouts stated clear
reasons for them, and numbers were similar in both groups (Bastu
2016; Ragni 2012; Schimberni 2016; Youssef 2011). We assessed
nine trials as at unclear risk of bias due to lack of information
regarding dropouts, the majority of these trials being conference
abstracts (Ashrafi 2005; Elnashar 2016; Fenichel 1988; Fujimoto
2014; Galal 2012; Ghosh Dastidar 2010; Jindal 2013; Nabati
2016; Weigert 2002). We assessed three trials as at high risk of
attrition bias, of which two studies had high dropout rates with-
out clearly stated reasons (Karimzadeh 2010; Tummon 1992),
and one study did not provide information regarding number of
women randomized (Jutras 1991).Wherever possible, we took the
denominator as the number of women randomized.
Selective reporting
None of the included studies appeared to publish or fail to pub-
lish any outcomes according to their statistical significance. Gen-
erally, few studies reported on live birth. There was a paucity of
information on side effects of the CC or Ltz protocols. Most stud-
ies reported cycle cancellation due to poor response; few reported
miscarriage rate and ectopic pregnancy rate; and only one trial
reported foetal abnormalities. There were no data on acceptability
of the adjuvant treatments.
Seven trials were published as conference abstracts (Elnashar 2016;
Fujimoto 2014; Galal 2012; Ghosh Dastidar 2010; Jindal 2013;
Jutras 1991; Schimberni 2016),making judgement difficult due to
lack of information. Five trials had a registered protocol available
(Bastu 2016; Lee 2012; Nabati 2016; Ragni 2012; Schimberni
2016).
Other potential sources of bias
One of the trial was at high risk of other bias (Ragni 2012). This
study was interrupted after the scheduled two years of recruitment
before reaching the sample size, leaving the study power at 60%
instead of the planned 80%. One of the reasons for premature
closure of the trial was slow recruitment.
We assessed studies published as conference abstracts as at unclear
risk of other bias due to lack of information (Elnashar 2016;
Fujimoto 2014; Galal 2012; Ghosh Dastidar 2010; Jindal 2013;
Jutras 1991; Schimberni 2016). The majority of the remaining
studies were at low risk for other bias.
Effects of interventions
See:Summaryof findings for themain comparisonClomiphene
citrate or letrozolewith or without gonadotropins (with or without
midcycle antagonist) compared to gonadotropins (with GnRH
agonists or midcycle antagonist) in IVF and ICSI cycles in
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general population for controlled ovarian stimulation; Summary
of findings 2 Clomiphene citrate or letrozole with or without
gonadotropins (with or without midcycle antagonist) compared
to gonadotropins (with GnRH agonist or midcycle antagonist)
in IVF and ICSI cycles in poor responders for controlled ovarian
stimulation
1. Clomiphene citrate or letrozole with or without
gonadotropins in conjunction with or without
midcycle antagonist versus gonadotropins (with
GnRH agonists or midcycle antagonist) in IVF and
ICSI cycles in the general IVF population
Wepooled results from 12 trials (1998 women) in this comparison
(Elnashar 2016; Fenichel 1988; Galal 2012; Grochowski 1999;
Harrison 1994; Karimzadeh 2010; Kingsland 1992; Lin 2006;
Long 1995;Mukherjee 2012; Tummon 1992; Weigert 2002). For
two included trials requisite data were not available for pooling
the results (Ghosh Dastidar 2010; Jutras 1991). In the interven-
tion group of one trial, both CC or Ltz was used along with go-
nadotropin, hence results could not be pooled (Jindal 2013).
Primary outcomes
1.1 Live-birth rate
Four studies reported live birth. There was no clear evidence of
a difference between the groups in live-birth rate (risk ratio (RR)
0.92, 95% confidence interval (CI) 0.66 to 1.27, 4 RCTs, n =
493, I2 = 0%, low-quality evidence) (Analysis 1.1; Figure 4). This
means that for a typical clinic with 23% success using a standard
GnRH agonist regimen, switching to CC would be expected to
result in live-birth rates between 15% and 30%. All four trials
compared CC protocol versus agonist protocol. None of the in-
cluded trials reported live-birth outcome for the other three sub-
groups. Sensitivity analysis done after removing studies without
clear randomization, or by switching to odds ratio (OR), did not
show any evidence of a difference in the live-birth rate.
Figure 4. Forest plot of comparison: 1 Clomiphene citrate or letrozole with or without gonadotropins in
conjunction with or without midcycle antagonist versus gonadotropins (with GnRH agonists or midcycle
antagonist) in IVF and ICSI cycles in general population, outcome: 1.1 Live birth.
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1.2 Ovarian hyperstimulation syndrome
Five studies reported OHSS. There was evidence of a decrease in
the incidence of OHSS when CC or Ltz protocol was used (Peto
OR 0.21, 95% CI 0.11 to 0.41, 5 RCTs, n = 1067, I2 = 0%,
low-quality evidence) (Analysis 1.2; Figure 5). This means that for
a typical clinic with a 6% prevalence of OHSS using a standard
GnRH regimen, switching to CC or Ltz protocol would be ex-
pected to reduce the incidence to between 0.5% and 2.5%. Sensi-
tivity analysis done after removing studies without clear random-
ization showed a persistent decrease in the incidence of OHSS
with CC or Ltz protocol.
Figure 5. Forest plot of comparison: 1 Clomiphene citrate or letrozole with or without gonadotropins in
conjunction with or without midcycle antagonist versus gonadotropins (with GnRH agonists or midcycle
antagonist) in IVF and ICSI cycles in general population, outcome: 1.2 Ovarian hyperstimulation syndrome.
Subgroup analysis according to the types of protocol compared
showed no evidence of a difference between the subgroups: test
for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 = 0%.
Secondary outcomes
1.3 Ongoing pregnancy rate
Only six studies reported the outcome of ongoing pregnancy.
There was no clear evidence of a difference between the groups in
ongoing pregnancy rate (RR 1.00, 95% CI 0.77 to 1.30, 6 RCTs,
n = 758, I2 = 0%) (Analysis 1.3). This means that for a typical
clinic with 23% success using a standard regimen, switching to
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CC protocol would be expected to result in pregnancy rates be-
tween 18% and 30%. None of the included trials reported ongo-
ing pregnancy outcome for the other three subgroups.
1.4 Clinical pregnancy rate
Twelve studies reported clinical pregnancy rate. There was no clear
evidence of a difference between the groups in clinical pregnancy
rate (RR 1.00, 95% CI 0.86 to 1.16, 12 RCTs, n = 1998, I2 = 3%,
moderate-quality evidence) (Analysis 1.4). This means that for a
typical clinic with 25% success using a standard regimen, switch-
ing to CC or Ltz would be expected to result in pregnancy rates
between 21% and 29%. Sensitivity analysis done after removing
studies without clear randomization did not show any evidence
of a difference in the clinical pregnancy rate (RR 1.10, 95% CI
0.89 to 1.37). Four studies reported adequate randomization. A
funnel plot for this outcome showed no evidence of publication
bias (Figure 6).
Figure 6. Funnel plot of comparison: 1 Clomiphene citrate or letrozole with gonadotropins in conjunction
with or without midcycle antagonist versus gonadotropins with GnRH protocols in IVF and ICSI cycles in
general population, outcome: 1.4 Clinical pregnancy rate.
Subgroup analysis according to the types of protocol compared
showed evidence of a difference between the subgroups: test for
subgroup differences: Chi2 = 7.76, df = 2 (P = 0.02), I2 = 74.2%.
All the heterogeneity in this analysis was due to a single study
comparing Ltz with follicle-stimulating hormone and antagonist
versus long protocol with follicle-stimulating hormone (Elnashar
2016), which reported a higher clinical pregnancy rate in the inter-
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vention group (RR 0.29, 95% CI 0.12 to 0.72). There was no ev-
idence of a difference between the groups in the other subgroups.
1.5 Cycle cancellation rate
Nine studies reported on the number of cycles cancelled due to
a poor response. There was evidence of an increase in cycle can-
cellation rate with the CC protocol compared to gonadotropins
in GnRH protocol (RR 1.87, 95% CI 1.43 to 2.45, 9 RCTs, n =
1784, I2 = 61%, low-quality evidence) (Analysis 1.5). This means
that for a typical clinic with 8%prevalence of cycle cancellation us-
ing a GnRH agonist regimen, switching to CC would be expected
to increase the incidence to between 11% and 20%. The increase
in cycle cancellation rate persisted even after adopting a random-
effects model (RR 1.74, 95%CI 1.01 to 3.00). Sensitivity analysis
done after removing studies with inadequate randomization did
not show any difference (RR 1.96, 95% CI 1.44 to 2.66).
1.6 Number of ampoules of gonadotropin
Six studies reported the number of ampoules of gonadotropins
used along with a measure of variance. The data were too het-
erogeneous to pool (I2=97%). All studies reported that CC plus
gonadotropins was associated with use of fewer ampoules than
gonadotropin-only regimens in agonist protocols, with the mean
difference ranging from 5.6 to 24.6 ampoules (Analysis 1.6). The
heterogeneity may be attributable to differences in the starting
dose of gonadotropins. Sensitivity analysis, whether by removing
studies with inadequate randomization or by using a random-ef-
fects model, showed persistent evidence of an increased require-
ment for gonadotropins in GnRH protocol.
1.7 Number of oocytes
Eight studies reported the number of oocytes retrieved, along with
ameasure of variance. Eight studies reported the number of oocytes
retrieved, along with a measure of variance. The data were too
heterogeneous to pool (I2=92%). In seven studies CC plus go-
nadotropins was associated with retrieval of fewer oocytes than
gonadotropin-only regimens in agonist protocols, with the mean
difference ranging from 1.02 to 6.20 oocytes. The difference was
statistically significant in five of these studies. The eighth study
made the same comparison and found no evidence of a differ-
ence between the groups. The heterogeneity may be attributable
to differences in the starting dose of gonadotropins (Analysis 1.7).
Sensitivity analysis, whether by removing studies with inadequate
randomization or by using a random-effects model, showed per-
sistent evidence of a decrease in the number of oocytes retrieved
with the CC with or without gonadotropins protocol compared
to gonadotropins in GnRH agonist protocol.
1.8 Multiple pregnancy rate
Five trials measured multiple pregnancy rate. There was no clear
evidence of a difference between the groups (RR 0.74, 95% CI
0.39 to 1.43, 5 RCTs, n = 791, I2 = 3%) (Analysis 1.8). Sub-
group analysis according to the types of protocol compared did
not suggest a difference between the subgroups: test for subgroup
differences: Chi2 = 0.30, df = 1 (P = 0.58), I2 = 0%.
1.9 Miscarriage rate
Seven trials reported miscarriage rate. There was no clear evidence
of a difference between the groups (RR 0.95, 95%CI 0.61 to 1.47,
7 RCTs, n = 1116, I2 = 0%) (Analysis 1.9). Subgroup analysis
according to the types of protocol compared did not suggest a
difference between the subgroups: test for subgroup differences:
Chi2 = 0.39, df = 1 (P = 0.53), I2 = 0%.
1.10 Ectopic pregnancy rate
Two trials reported ectopic pregnancy rate. There was no clear
evidence of a difference between the groups (Peto OR 7.56, 95%
CI 0.47 to 120.94, 2 RCTs, n = 223, I2 = 0%) (Analysis 1.10).
1.11 Foetal abnormalities
Only one trial reported the rate of foetal abnormalities (Harrison
1994). There were no reported cases of foetal abnormalities within
the two groups.
2. Clomiphene citrate or letrozole with or without
gonadotropins in conjunction with or without
midcycle antagonist versus gonadotropins (with
GnRH agonists or midcycle antagonist) in IVF and
ICSI cycles in poor responders
We could pool results from 10 trials (1601 women) in this com-
parison (Ashrafi 2005; Bastu 2016; Goswami 2004; Lee 2012;
Mohsen 2013; Nabati 2016; Pilehvari 2016; Ragni 2012; Revelli
2014; Youssef 2011). As one trial reported only cumulative live-
birth rate, we could not pool results (Fujimoto 2014). Another
trial evaluated CC with gonadotropin with antagonist versus two
control arms of short agonist protocol and antagonist protocol
(Schimberni 2016), hence due to two different control arms we
could not pool the data.
Primary outcomes
2.1 Live-birth rate
Two studies reported live-birth rate. There was no clear evidence
of a difference between the groups (RR 1.16, 95% CI 0.49 to
2.79, 2 RCTs, n = 357, I2 = 38%, low-quality evidence) (Analysis
2.1; Figure 7). This means that for a typical clinic with 5% success
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using a standard GnRH analogue regimen, switching to CC or Ltz
with gonadotropin would be expected to result in live-birth rates
between 2% and 14%. Sensitivity analysis performed by changing
summarymeasure effect to odds ratio or adopting a random-effects
model did not show evidence of a difference in live-birth rate.
Figure 7. Forest plot of comparison: 2 Clomiphene citrate or letrozole with or without gonadotropins in
conjunction with or without midcycle antagonist versus gonadotropins (with GnRH agonist or midcycle
antagonist) in IVF and ICSI cycles in poor responders, outcome: 2.1 Live birth.
Subgroup analysis according to the types of protocol compared
showed no evidence of a difference between the subgroups: test for
subgroup differences: Chi2 = 1.61, df = 1 (P = 0.21), I2 = 37.7%.
2.2 Ovarian hyperstimulation syndrome
This outcome was not applicable to this population.
Secondary outcomes
2.3 Ongoing pregnancy rate
Only two studies reported ongoing pregnancy rate. There was no
clear evidence of a difference between the groups (RR 0.86 , 95%
CI 0.58 to 1.28, 2 RCTs, n = 748, I2 = 53%) (Analysis 2.2). This
means that for a typical clinic with 12% success using a standard
regimen, switching to CC or Ltz protocol would be expected to
result in pregnancy rates between 7%and 16%. Sensitivity analysis
done using a random-effects model did not suggest a difference
(RR 1.12, 95% CI 0.38 to 3.28).
Subgroup analysis according to the types of protocol compared did
not suggest a difference between the subgroups: test for subgroup
differences: Chi2 = 2.14, df = 1 (P = 0.14), I2 = 53.4%.
2.4 Clinical pregnancy rate
Eight studies reported clinical pregnancy rate. There was no clear
evidence of a difference between the groups (RR 0.85, 95% CI
0.64 to 1.12, 8 RCTs, n = 1462, I2 = 0%, low-quality evidence)
(Analysis 2.3). This means that for a typical clinic with 13% suc-
cess using a standard regimen, switching to CC or Ltz protocol
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would be expected to result in pregnancy rates between 8% and
14%. Sensitivity analysis done after excluding studieswithout clear
randomization did not show any evidence of a difference in clin-
ical pregnancy rate (RR 0.92, 95% CI 0.68 to 1.23). Six studies
had adequate randomization.
Subgroup analysis according to the types of protocol compared did
not suggest a difference between the subgroups: test for subgroup
differences: Chi2 = 1.64, df = 3 (P = 0.65), I2 = 0%.
2.5 Cycle cancellation rate
Ten studies reported on the number of cycles cancelled due to a
poor response. There was evidence of an increase in cycle can-
cellation rate with the CC or Ltz with or without gonadotropin
compared to gonadotropins in GnRHprotocol (RR 1.46, 95%CI
1.18 to 1.81, 10 RCTs, n = 1601, I2 = 64%, low-quality evidence)
(Analysis 2.4). Thismeans that for a typical clinic with 14% preva-
lence of cycle cancellation using a GnRH regimen, switching to
CC or Ltz protocol would be expected to increase the incidence
to between 17% and 26%. The increase in cycle cancellation rate
did not differ after adopting a random-effects model (RR 1.35,
95% CI 0.93 to 1.98). Sensitivity analysis after removing studies
with inadequate randomization revealed persistence of difference
(RR 1.48, 95% CI 1.16 to 1.89).
Subgroup analysis according to the types of protocol compared did
not suggest a difference between the subgroups: test for subgroup
differences: Chi2 = 5.10, df = 3 (P = 0.16), I2 = 41.2%.
2.6 Mean number of ampoules of gonadotropin used
Three studies reported the number of ampoules of gonadotropins
used along with a measure of variance.
In two studies the intervention group received CC plus go-
nadotropins and in the other one the intervention group received
letrozole. These subgroups were too heterogeneous to pool (I2=
96%) and the test for subgroup differences between the subgroups
was statistically significant: Chi2 = 56.37, df = 1 (P < 0.001), I2 =
98.2%.
Comparedwith use of gonadotropin-only regimens in agonist pro-
tocols, there was evidence of a decrease in the mean number of
ampoules used associated with the use of CC plus gonadotropins
(MD -23.98, 95% CI -27.41 to -20.56; participants = 87; studies
= 2; I2 = 0%) and also with the use of letrozole plus gonadotropins
(MD -46.24, 95% CI -50.93 to -41.55; participants = 49; studies
= 1) (Analysis 2.5).
Sensitivity analysis done using a random-effects model showed
persistent evidence of an increased requirement for gonadotropins
in GnRH agonist protocols.
2.7 Mean number of oocytes retrieved
Eight studies reported the number of oocytes retrieved, along with
a measure of variance.
Four of these studies compared CC plus gonadotropins versus go-
nadotropins in an agonist protocol. One study compared CC plus
gonadotropins versus gonadotropins in an antagonist protocol,
and three studies compared letrozole plus gonadotropins versus
gonadotropin only in an agonist protocol. The studies were too
heterogeneous to pool, either overall (I2=83%) or within protocol
subgroups (I2=85%-88%). However, in seven of the eight studies
the direction of effect was consistent and was associated with infe-
rior findings in the intervention group. The heterogeneity may be
attributable to differences in the starting dose of gonadotropins
In three studies CC plus gonadotropins was associated with re-
trieval of fewer oocytes than gonadotropin-only regimens in ago-
nist protocols, with themean difference ranging from 0.75 to 2.10
oocytes. The difference was statistically significant in two of these
studies. The fourth study found no clear evidence of a difference
between the groups, and the direction of effect was inconsistent
with the other three studies.
The study comparing CC plus gonadotropins versus a go-
nadotropin-only regimen in an antagonist protocol found no clear
evidence of a difference between the groups (MD -0.59, 95%
CI -1.58 to 0.40; participants = 54; studies = 1). Findings were
mixed in the studies comparing letrozole plus gonadotropins ver-
sus gonadotropin only in an agonist protocol: one study reported
retrieval of significantly fewer oocytes in the intervention group,
while the other two studies found no clear evidence of a difference
between the groups. Analysis 2.6
Sensitivity analysis whether by removing the studies with inade-
quate randomization or by using a random-effects model for anal-
ysis showed persistent evidence of a decrease in the number of
oocytes retrieved with the CC or Ltz protocol compared to GnRH
protocol.
Subgroup analysis according to the types of protocol compared did
not suggest a difference between the subgroups: test for subgroup
differences: Chi2 = 5.78, df = 2 (P = 0.06), I2 = 65.4%.
2.8 Multiple pregnancy rate
Only one trial reported multiple pregnancy rate. There was no
clear evidence of a difference between the groups (RR 0.53, 95%
CI 0.05 to 5.75, 1 RCT, n = 304) (Analysis 2.7).
2.9 Miscarriage rate
Three trials reported miscarriage rate. There was no clear evidence
of a difference between the groups (RR 0.97, 95% CI 0.45 to
2.12, 3 RCTs, n = 818, I2 = 2%) (Analysis 2.8).
2.10 Ectopic pregnancy
No trials reported on this outcome.
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2.11 Foetal abnormalities
Only one trial reported the rate of foetal abnormalities (Ragni
2012). There were no reported cases of foetal abnormalities in
either group.
Other analyses
We examined publication bias in this systematic review by con-
structing a funnel plot. There was a paucity of trials reporting live-
birth data. We considered a funnel plot for the clinical pregnancy
data, using this as a surrogate endpoint. We observed symmetric
distribution of studies around the vertical line, indicating no pub-
lication bias (Figure 6).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Clomiphene citrate or letrozole with or without gonadotropins (with or without midcycle antagonist) compared to gonadotropins (with GnRH agonist or midcycle antagonist)
in IVF and ICSI cycles in poor responders for controlled ovarian stimulation
Patient or population: Women undergoing controlled ovarian st imulat ion in IVF and ICSI cycles (poor responders)
Setting: Assisted reproduct ion clinic
Intervention: Clomiphene citrate or letrozole with or without gonadotropins (with or without m idcycle antagonist)
Comparison: Gonadotropins (with GnRH agonist or m idcycle antagonist)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with
gonadotropins (with
GnRH agonist or mid-
cycle antagonist)
Risk with clomiphene
citrate or letrozole
with or without go-
nadotropins (with or
without midcycle an-
tagonist)
Live birth per woman 49 per 1000 57 per 1000
(24 to 137)
RR 1.16
(0.49 to 2.79)
357
(2 RCTs)
⊕⊕©©
LOW1,2
Clinical pregnancy rate
per woman
128 per 1000 109 per 1000
(82 to 143)
RR 0.85
(0.64 to 1.12)
1462
(8 RCTs)
⊕⊕©©
LOW1,2
Cancellation rate per
woman
145 per 1000 212 per 1000
(171 to 263)
RR 1.46
(1.18 to 1.81)
1601
(10 RCTs)
⊕⊕©©
LOW 1,3
Mean number of go-
nadotropin ampoules
used per woman
The mean number of
ampoules used in the
control group ranged
f rom 39 to 71
There were fewer am-
poules used in the inter-
vent ion groups (CC plus
gonadotropins: MD -
23.98, 95% CI -27.41
to -20.56; part icipants
= 87; studies = 2)
; letrozole plus go-
- 136
(3 RCTs)
⊕⊕⊕©
MODERATE1,4
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nadotropins: MD -46.
24, 95%CI -50.93 to -41.
55; part icipants = 49;
studies = 1)
Mean
number of oocytes re-
trieved per woman
The mean number
oocytes retrieved in the
control group ranged
f rom 2 to 5
In three of four studies
CC plus gonadotropins
versus gonadotropins
in an agonist protocol
was associated with re-
trieval of fewer oocytes,
with the mean dif fer-
ence ranging f rom 0.
75 to 2.10 oocytes.
The dif ference was sta-
t ist ically signif icant in
two of these stud-
ies. One study found
no evidence of dif -
ference between CC
plus gonadotropin ver-
sus gonadotropin in
an antagonist proto-
col. Of three stud-
ies comparing letrozole
plus gonadotrophins,
one study reported sig-
nif icant ly lower oocyte
retrieval while the other
two studies found no
clear evidence of a dif -
ference
- 1203
(8 RCTs)
⊕⊕⊕©
MODERATE1,4
*The risk in the intervention group (and its 95% conf idence interval) is based on the mean risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; GnRH: gonadotropin-releasing hormone; ICSI: intracytoplasmic sperm inject ion; IVF: in vit ro fert ilisat ion; MD: mean dif ference; RCT: randomised
controlled trial; RR: risk rat io25
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of the ef fect
1Downgraded one level (serious risk of bias). Many of the included studies had unclear risk of bias for allocat ion concealment.
2Downgraded one level (serious imprecision). Conf idence interval is wide and compatible with benef it in either group, or with
no ef fect.
3Downgraded one level (serious inconsistency). I2 64%.
4Not downgraded for inconsistency. Although there was high stat ist ical heterogeneity, this referred to the magnitude of
dif f erence rather than direct ion of evidence.
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D I S C U S S I O N
Summary of main results
The main finding of this updated systematic review was that it
is unclear whether the use of clomiphene citrate (CC) or letro-
zole (Ltz) with gonadotropins, with or without GnRH antago-
nist, in controlled ovarian stimulation in IVF leads to a difference
in live-birth rates, ongoing pregnancy rates, or clinical pregnancy
rates when compared to the use of gonadotropins with GnRH
protocols in either the general population of women undergoing
IVF( Summary of findings for themain comparison) or in women
who are poor responders (Summary of findings 2). The use of
CC or Ltz led to a significant increase in cycle cancellation rate
(low-quality evidence) as well as a reduction in the incidence of
OHSS (in a general IVF population) (low-quality evidence), the
number of gonadotropins ampoules used (moderate-quality ev-
idence) and number of oocytes retrieved (moderate-quality evi-
dence) (Summary of findings for themain comparison) (Summary
of findings 2). In most included studies, it was not possible to de-
termine whether cycle cancellation was due to premature luteinis-
ing hormone surge, poor follicular development, or other reasons.
Although our results showed that there may be fewer oocytes re-
trieved with the use of CC or Ltz protocols in both the general IVF
population and poor responders, these data must be interpreted
with caution as there were no differences in pregnancy or live-
birth rates, which are more relevant outcomes. Some studies may
have failed to count zero entries for participants with cancelled
cycles, which may have affected the overall estimate of difference,
particularly if cancellation was more common in the CC or Ltz
arms.
Overall completeness and applicability of
evidence
We performed a sample size calculation, which found that for
a study to detect a 5% difference in live birth with 80% power
and 0.05 significance level, when the live-birth rate in the control
group is 20%, an individual trial would need to randomise over
2000 women (STATA 10.1 software)(STATA). This means that if
there is truly no difference between standard gonadotropins and
CC protocols, then more than 2000 patients are required to be
80% sure that the limits of a two-sided 90% confidence interval
will exclude a difference between standard and new treatments of
more than 5%. Unfortunately, the total number of participants in
studies included in this meta-analysis was insufficient to identify
this minimal effective difference. We therefore acknowledge that
a type 2 (beta) statistical error cannot be excluded.
Most of the studies included in the meta-analysis suffered from an
inadequate description of allocation concealment. This limits the
level of confidence associated with this meta-analysis. None of the
trials addressed the potential value of any surplus embryos that
could have been frozen for later use. Most of the included trials
did not assess cumulative live birth after pooling results from fresh
and cryo-thawed cycles. One included trial reported comparable
cumulative live-birth rates following CC and GnRH antagonist
protocol in poor responders (Fujimoto 2014). Comparative non-
randomised studies have shown inconsistent results (Demoulin
1991; Fugger 1991; Van der Elst 1996). There are no data on
the acceptability of CC- or Ltz-included protocols. The adverse
effects of these protocols have been poorly reported.Data on foetal
abnormalities following the use of CC or Ltz protocols are also
lacking.
The primary outcome of this reviewwas live-birth rate per woman.
The lack of adequately powered trials and possible clinical het-
erogeneity among the included trials suggest that the evidence
is insufficient to effectively draw conclusions on the value of
CC or Ltz alone or in combination with gonadotropins, with or
without GnRH antagonist, compared to conventionally used go-
nadotropins and GnRH agonist protocols in the general IVF pop-
ulation. In the poor responder group, the different criteria used
to define inclusion limits the overall applicability of evidence even
within this population.
Heterogeneity
We observed the presence of variations in criteria among indi-
vidual trials in terms of the definition of pregnancy, the types
and doses of gonadotropins, GnRH agonist used, age, method
of monitoring follicular response, type of intervention (IVF or
ICSI), luteal support, starting doses of gonadotropins, causes of
cycle cancellation, and type of GnRH protocols (agonist and an-
tagonist). In addition, there was variation in inclusion for poor
responders among the included studies. The literature suggests no
difference in pregnancy rates between a long intramuscular depot
and different preparations of subcutaneous short-acting GnRH
agonists (Albuquerque 2013; Wong 2001). Meanwhile, urinary
human menopausal gonadotropin has not been demonstrated to
be superior to recombinant follicle-stimulating hormone in terms
of live-birth rate after IVF treatment (van Wely 2011). The long
luteal GnRH agonist has been observed to have better results than
short protocol (Siristatidis 2015). Clinical heterogeneity among
studies was also due to variations in the trials’ protocols as well as
the inclusion and exclusion criteria for recruited patients.
We found high statistical heterogeneity for some of the outcomes
studied in this review. The statistically significant increase in cy-
cle cancellation rate (I2 = 61% to 64%) whenever CC or Ltz was
used, and the statistically significant reductions in number of go-
nadotropins ampoules used (I2 = 96% to 97%) and suggestion
of fewer oocytes retrieved (I2 = 83% to 92%) should therefore
be interpreted with caution. Differences in the starting doses of
gonadotropins may affect the total number of gonadotropins am-
poules used as well as the number of oocytes. Meanwhile, differ-
ences in causes for cycle cancellation like poor follicular develop-
ment or premature luteinising hormone surge may be a strong
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contributor to this observed statistical heterogeneity for the men-
tioned outcomes.
Quality of the evidence
Most studies included in the original review had suboptimal
methodology. We included 27 trials in the current update, 13 of
which were from the original review.We included 22 studies in the
meta-analysis. There was insufficient information for some out-
comes, and only six trials reported live-birth rate per woman or
couple. The method of randomisation was unclear in some trials.
Most studies had small sample sizes. Most studies lacked blinding.
A funnel plot for the outcome of clinical pregnancy in the general
IVF population showed no evidence of publication bias (Figure
6).
Some of the studies comparing CC with gonadotropins versus
gonadotropins in GnRH protocol in a general population of
women undergoing IVF and ICSI were very old. Only one rele-
vant study has been published within the last 15 years (Weigert
2002). Hence no recent data have been published for this com-
parison, although new studies comparing Ltz plus gonadotropins
versus gonadotropins only in GnRHprotocols have been included
(Elnashar 2016; Galal 2012; Mukherjee 2012). Most of the new
trials included in this update evaluated CC or Ltz in poor re-
sponders, but only two trials reported live birth (Lee 2012; Ragni
2012).
In the general IVF population, the overall quality of evidence was
low for live birth, OHSS, and cancellation rate and moderate for
clinical pregnancy, gonadotropins requirement, and mean oocytes
retrieved. The main limitations were risk of bias (due to unclear
allocation concealment) and imprecision associated with low fre-
quency of events. In the poor responder group, the overall quality
of evidence was low for live birth, clinical pregnancy, and can-
cellation rate and moderate for gonadotropins requirement and
numbers of oocytes retrieved. The evidence was limited by serious
imprecision and risk of bias. We noted a high level of statistical
heterogeneity for the outcomes of cancellation rate, gonadotropins
dose, and oocytes retrieved, which was due to the use of different
protocols and cancellation policies in the trials. We did not down-
grade the level of evidence for inconsistency for gonadotropins us-
age and oocytes retrieved since the statistical heterogeneity referred
to the magnitude of difference rather than direction of evidence.
Potential biases in the review process
We aimed to identify all eligible studies for this update. Whenever
possible, we contacted study authors for additional information
for potential inclusion in the review. However, for many confer-
ence abstracts, we had difficulty contacting authors and getting
necessary information and data.
Agreements and disagreements with other
studies or reviews
A recent systematic review evaluated the role of CC and Ltz dur-
ing ovarian stimulation in women undergoing IVF (Bechtejew
2017). The review included 23 studies, and separate pooled results
were available for women with expected poor response and women
without risk of poor response. The live-birth rate (RR 0.90, 95%
CI 0.6 to 1.2) and clinical pregnancy rate (RR 1.02, 95% CI 0.8
to 1.4) did not differ significantly between the groups in poor re-
sponders, and mean consumption of gonadotropins was signifi-
cantly lower following CC (MD -18, 95% CI -21 to -15) and Ltz
(MD -35, 95% CI -47 to -23) protocol in the same population.
In women who were not at risk of poor response, the live-birth
rate (RR 0.90, 95% CI 0.7 to 1.1) and clinical pregnancy rate (RR
1.00, 95% CI 0.9 to 1.2) did not differ significantly between the
two groups. There was a significant difference in OHSS rate (Peto
OR 0.20, 95% CI 0.1 to 0.3) and gonadotropins consumption
following CC protocol. The findings of Bechtejew 2017 are in
agreement with the current update for all important outcomes for
a general IVF population and poor responders.
Another systematic review evaluated CC protocol versus stan-
dard GnRH protocol in poor responders and included three ran-
domised trials and one quasi-randomised trial (Song 2016). The
pooled results did not show any significant difference in live birth
(OR 0.71, 95% CI 0.22 to 2.29) and clinical pregnancy (OR
1.11, 95% CI 0.80 to 1.55) rates between the two groups. These
findings are in agreement with the findings of the current review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found no conclusive evidence indicating that clomiphene cit-
rate or letrozole with or without gonadotropins differed from go-
nadotropins in gonadotropin-releasing hormone agonist or antag-
onist protocols in terms of their effects on live birth or pregnancy
rates, either in the general population of women undergoing in
vitro fertilisation (IVF) treatment or in women who were poor re-
sponders. Use of clomiphene citrate or letrozole led to a reduction
in the amount of gonadotropins required and the incidence of
ovarian hyperstimulation syndrome. However, use of clomiphene
citrate or letrozole may be associated with a significant increase in
the incidence of cycle cancellations, as well as reductions in the
mean number of oocytes retrieved in the general IVF population
and poor responders. Larger, high-quality randomised trials are
needed to reach a firm conclusion before clomiphene citrate or
letrozole are adopted into routine clinical practice.
Implications for research
There is a need for an adequately powered randomised trial com-
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paring clomiphene citrate or letrozole along with gonadotropins
versus gonadotropins-alone protocols for controlled ovarian stim-
ulation in IVF treatment to assess clinical and cost-effectiveness
as well as the acceptability of the regimens in both the general
IVF population and in poor responders. Cumulative live birth af-
ter fresh and cryo-thawed cycles should also be investigated. Out-
come measures should include cost per live birth as well as patient
satisfaction.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ashrafi 2005
Methods RCT
Participants 154 poor responders who had undergone at least 1 previous IVF attempt with a poor
response. Responses were assessed as poor when baseline follicle-stimulating hormone
concentration was > 15 mIU/mL, oestradiol concentration on the day of hCG injection
was < 500 pg/mL, or the number of pre-ovulatory follicles > 16 mm in diameter was
fewer than 3
Interventions 45 women went into the hMG group, 52 women into the GnRH agonist plus hMG
group, and 34 women into the CC plus hMG group
Outcomes Premature LH surges, cycles cancelled in the follicular phase, and the number of mature
oocytes retrieved
Notes Authors were contacted for the missing data through email but they did not respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This is an RCT, although method of random sequence genera-
tion was not mentioned
Allocation concealment (selection bias) Unclear risk Sealed envelopes (there was no mention of whether they were
opaque or not or whether serially numbered or not)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Although blinding was not mentioned, we did not consider that
blinding was likely to influence findings for our primary and
secondary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up and missing data information was not men-
tioned. Information unclear to make a judgement
Selective reporting (reporting bias) High risk Most of the reported outcomes were surrogate outcomes, and
there was no mention of our primary and secondary outcomes
(i.e. live birth and OHSS)
Other bias Unclear risk We contacted the authors for missing data but received no re-
sponse
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Bastu 2016
Methods RCT
Country: Turkey
Single-centre
Participants Included poor responders by Bologna criteria (2 out of 3) ≥ 40 years or other risk factor
for POR or abnormal ovarian test or previous ≤ 3 oocytes retrieved
Age 18 to 42; normal uterus by HSG or hysteroscopy; regular cycles; normal hormonal
cycles; BMI 19.3 to 28.9; ejaculate sample; no endocrine abnormalities
Exclusion: history of gonadotoxic therapy; ovarian surgery; natural IVF;DHEAor testos-
terone supplement
Interventions Group 1 (n = 31): gonadotropins 450 (hMG + recombinant) + antagonist
Group 2 (n = 31): gonadotropins 300 (hMG + recombinant) + antagonist
Group 3 (n = 33): mild stimulation: letrozole 5 days, 5 mg/day + hMG 150 IU +
antagonist
Outcomes Clinical pregnancy rate; ongoingpregnancy rate; implantation rate; gonadotropins usage;
mean number of oocytes; cycle cancellation rate
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation described “computer generated
list”.
Allocation concealment (selection bias) Unclear risk “Sealed envelope used”; does not mention
whether opaque or numbered
Blinding (performance bias and detection
bias)
All outcomes
Low risk Clinician and embryologist blinded. Overall we
did not consider that blinding was likely to in-
fluence findings for our primary and secondary
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up reported, and cancellation
across groups was balanced. An intention-to-
treat analysis was done
Selective reporting (reporting bias) High risk Even though clinical and ongoing pregnancy
rates were stated outcomes, in the results these
outcomes were clubbed and presented as a single
outcome
Other bias Unclear risk Funding not mentioned.
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Elnashar 2016
Methods RCT
Country: Egypt
Single-centre
Participants Included normoresponders; unexplained infertility; AFC > 5, AMH > 1 ng/mL; BMI
18 to 29; age 20 to 35
Exclusion criteria: endometriosis; azoospermia; BMI > 29.
Interventions Group 1 (n = 40): letrozole 10 mg daily day 3 to 7 along with FSH 75 IU/day from day
5 along with antagonist
Group 2 (n = 40): long protocol with FSH 150 to 225 IU/day.
Outcomes Clinical pregnancy rate; total gonadotropins usage; mature oocytes retrieved
Notes Conference abstract
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not clearly stated.
Allocation concealment (selection bias) Unclear risk Used “sealed envelopes”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not enough information to make a judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not enough information to make a judgement.
Intention-to-treat analysis or loss to follow-upwas
not mentioned
Selective reporting (reporting bias) Unclear risk Not enough information to make a judgement,
event rates are not mentioned
Other bias Unclear risk There is not enough information tomake a judge-
ment. This is a conference abstract publication
Fenichel 1988
Methods RCT
Participants 30 women under age of 38 years with only tubal infertility and fertile semen samples
from their partners
Interventions 3-arm study:
Group I: clomiphene + hMG
Group II: triptorelin (Decapeptyl Depot) (3.5 mg) from day 22 of the preceding cycle
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Fenichel 1988 (Continued)
+ hMG after desensitisation (long protocol)
Group III: both GnRHa and hMG from day 2 of the cycle until day of hCG adminis-
tration (short protocol)
Outcomes Pregnancy rate, cancellation rate, premature LH surge, mean number of hMG ampoules,
mean number of oocytes
Notes Article in French
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This an RCT, however the method of random sequence gener-
ation was not described
Allocation concealment (selection bias) Unclear risk Although the authors stated in their study that “women were
not aware of their allocation”, the method of concealment of
allocation was not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The analysis was per cycle. Not enough information to make a
judgement
Selective reporting (reporting bias) Low risk The protocol of the study was not available, however most out-
comes of interest in this review were reported
Other bias Low risk We found no potential sources of within-study bias.
Fujimoto 2014
Methods RCT
Country: Japan
Recruitment: poor responder patients who visited the IVFCenter of University of Tokyo
Hospital for the purpose of ART
Participants 99 women undergoing ART
Inclusion criteria: elevated basal serum FSH levels (> 10 mIU/mL); antral follicle counts
< 7 in early follicular phase; previous poor response to ART treatment (< 5 retrieved
oocytes)
Exclusion criteria: over the age of 45; women who underwent oocyte retrieval cycles
more than 3 times
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Fujimoto 2014 (Continued)
Interventions Group 1 (n = 44): controlled ovarian stimulation initiated on day 3 with 5 days of
clomiphene citrate (2 tabs daily) followed by hMG administration. After leading follicle
diameter reached 14 mm, GnRH antagonist Ganirelix was administered in addition to
hMG
Group 2 (n = 45): hMG administration was started on day 3, followed by combination
with Ganirelix as above
Outcomes Cumulative live-birth rate per woman; cancellation rate
Other outcomes reported in study but not entered into review: fertilisation rate; oestradiol
levels on day of trigger; number of growing follicles
Notes Number of events not reported. This was a conference absract. We could not contact
the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation process not described.
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk There was no description of blinding par-
ticipants, personnel, or outcome assess-
ment in this conference abstract. However,
we did not consider that potential lack of
blinding was likely to influence findings for
our primary and secondary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not enough information to make a judge-
ment. Intention-to-treat analysis or loss to
follow-up was not mentioned
Selective reporting (reporting bias) Unclear risk Not enough information to make a judge-
ment, event rates are not mentioned
Other bias Unclear risk There is not enough information to make
a judgement. This is a conference abstract
publication
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Galal 2012
Methods RCT
Country: Egypt
Single-centre
Participants Women with PCOS and planned for ICSI
Interventions Mild stimulation (n = 20): letrozole 10 mg day 2 to 6 along with hMG (150 to 225 IU)
Conventional stimulation (n = 20): hMG (150 to 225 IU) in antagonist protocol
Outcomes Main outcomes were gonadotropins use, day of stimulation, mean oocytes retrieved, and
clinical pregnancy rate
Notes Number of events not reported. This was a conference abstract
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described.
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk There was no description of blinding participants,
personnel, or outcome assessment in this confer-
ence abstract
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not enough information to make a judgement.
Intention-to-treat analysis or loss to follow-upwas
not mentioned
Selective reporting (reporting bias) Unclear risk Not enough information to make a judgement,
event rates are not mentioned
Other bias Unclear risk There is not enough information tomake a judge-
ment. This is a conference abstract publication
Ghosh Dastidar 2010
Methods RCT
Participants 116 good-prognosis patients undergoing their first IVF cycle
Interventions Women were randomised into 2 groups. Group A participants received clomiphene
citrate from day 2 to day 6 of cycle and rFSH (100 to 150 IU) on days 3 and 5 and then
daily from day 7 onwards. GnRH antagonist (0.25mg) was administered subcutaneously
daily once lead follicle measured 13 to 14 mm until day of hCG. GnRHa protocol and
ovarian stimulation with rFSH (200 to 225 IU starting dose) was started in Group B
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Ghosh Dastidar 2010 (Continued)
Outcomes Pregnancy rate, implantation rate, number of top-quality embryos
Notes The abstract did not report the number of women assigned to each group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of intention-to-treat analysis
Selective reporting (reporting bias) Unclear risk No available protocol
Other bias Unclear risk The study was published as an abstract, and the authors did not
reply to our emails
Goswami 2004
Methods RCT
Country: India
Single-centre
Participants Women who had previous 1 to 3 IVF failures due to poor response were included.
Women with severe endometriosis, FSH > 12 IU, and history of previous pelvic surgery
were excluded. Women were randomised in a 1:2 ratio
Interventions Mild stimulation (n = 13): letrozole 2.5 mg from day 3 to 7 along with recombinant
FSH (75 IU) from day 3 to 8
Conventional protocol (n = 25): long agonist protocol with FSH
Outcomes Main outcomes were total dose of gonadotropins, oocytes retrieved, endometrial thick-
ness, and clinical pregnancy rates
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Goswami 2004 (Continued)
Random sequence generation (selection
bias)
Low risk Randomised using “random number table” by
study co-ordinator
Allocation concealment (selection bias) Unclear risk “Sequentially number sealed envelopes were used”
for allocation concealment. However, there was no
mention of whether the envelopes were opaque or
not
Blinding (performance bias and detection
bias)
All outcomes
Low risk Single-blinding of clinician done. We did not con-
sider that blinding was likely to influence findings
for our primary and secondary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised women were included in the anal-
ysis. No loss to follow-up or missing data reported
Selective reporting (reporting bias) Low risk All the outcomesmentioned inmaterial andmeth-
ods section were reported
Other bias Low risk We did not find any other source of bias within
the study.
Grochowski 1999
Methods RCT
Participants 324 infertile couples undergoing IVF/ICSI
Inclusion criteria: women younger than 36 years of age, regularly menstruating, and
cause of infertility indicates IVF/ICSI
Exclusion criteria: not mentioned
Interventions 2 groups:
Group A: clomiphene citrate + hMG
Group B: GnRHa (long) + hMG
Outcomes Pregnancy rate, implantation rate, cancellation rate, multiple pregnancy, OHSS rate,
mean number of oocytes retrieved, mean number of gonadotropins
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This is an RCT, however the method of random sequence gen-
eration was not described
Allocation concealment (selection bias) Unclear risk Serially numbered, closed envelopes, however there was nomen-
tion of whether they were opaque or not
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Grochowski 1999 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis done. No missing data or loss to fol-
low-up reported
Selective reporting (reporting bias) Low risk A duplicate publication for this study was checked and the trial
appears to be free from selective reporting
Other bias Low risk We found no other potential sources of within-study bias.
Harrison 1994
Methods RCT
Participants 150 women undergoing IVF for the first time
Interventions 150 women were randomised into 3 groups of 50 women each.
Group A: triptorelin intramuscularly from day 1 of the cycle, and hMG was given daily
when down regulation occurred
Group B: 100 mg clomiphene citrate from day 2 for 5 days with hMG daily from day
4 of the cycle
Group C: buserelin intranasally from day 1, and hMGwas added when down regulation
was confirmed
Outcomes Live-birth rate, pregnancy rates
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomised code
Allocation concealment (selection bias) Unclear risk Although quoted “patient allocation was performed by a second
party and clinicianswere blinded topatient allocation”, therewas
no description of how allocation concealment was performed
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although intention-to-treat analysis was not mentioned in the
study, we easily retrieved all data required from the published
material with no need to contact the authors
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Harrison 1994 (Continued)
Selective reporting (reporting bias) Low risk The protocol of the study was not available, however most out-
comes of interest were reported
Other bias Low risk We found no other potential sources of within-study bias.
Jindal 2013
Methods RCT
Country: India
Single-centre
Participants Women < 40 years, no further details
Interventions Mild stimulation (n = 173): clomiphene citrate or aromatase inhibitor for the first 5 days
of cycle followed by gonadotropins and 0.25 mg antagonist (cetrorelix) injection daily
until the day of hCG
Long GnRH analogue protocol (n = 173)
Outcomes gonadotropins usage, mean number of oocytes retrieved, clinical pregnancy rate
Outcomes reported but not used in review: cost of the oral ovulation induction agents
Notes This was published as a conference abstract.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using “computer generated list”.
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Notmention of any loss to follow-up. Information
insufficient to make a judgement
Selective reporting (reporting bias) Low risk All outcomes mentioned inmaterials andmethods
section were reported
Other bias Unclear risk The trial was not registered. Funding not men-
tioned.
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Jutras 1991
Methods RCT
Participants Women undergoing their first IVF cycle
Interventions CC + hMG versus gonadotropins in GnRH agonist short protocol
Outcomes Number of gonadotropins ampoules and midluteal progesterone
Notes This trial was published as an abstract. Number of participants was not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
High risk The total number of participants was not mentioned.
Selective reporting (reporting bias) Unclear risk No important outcomes of interest were reported. Not enough
information to make a judgement
Other bias Unclear risk The study was published as an abstract and the authors did not
reply to our emails
Karimzadeh 2010
Methods RCT
Participants 243 women who were candidates for ART
Inclusion criteria: women aged 18 to 35 years, presence of a regular and proven ovulatory
menstruation cycle with a length of 26 to 35 days, basal FSH < 10 IU/L, BMI 18 to
30 kg/m2, and first IVF attempt. Indications for IVF were unexplained infertility, male
factor, tubal factor, early-stage endometriosis, and cervical factor
Interventions Group A: GnRHa every day for menstrual cycle 21 until day of desensitisation, then
ovarian stimulation would commence with rFSH.
Group B: stimulated with clomiphene citrate and continuous gonadotropins stimulation
with rFSH. GnRH antagonist was started daily with dominant follicle 12 mm
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Karimzadeh 2010 (Continued)
Outcomes Pregnancy rate, implantation rate, cancellation rate, multiple pregnancy, OHSS rate,
mean number of oocytes retrieved, mean number of gonadotropins
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation schedule
Allocation concealment (selection bias) Unclear risk Sealed envelopes, however there was nomention of whether they
were opaque or not
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
High risk No intention-to-treat analysis, however data for number of
women who started treatment were provided and so could be
calculated in meta-analysis; besides percentage of dropouts was
above 5%
Selective reporting (reporting bias) Low risk The protocol of the study was not available, however most out-
comes of interest were reported
Other bias Low risk We found no other potential sources of within-study bias.
Kingsland 1992
Methods RCT
Participants 308 women undergoing their first IVF cycle
Interventions 4-arm study:
Group A: hMG (alone)
Group B: clomiphene citrate + hMG
Group C: GnRH agonist from first day of the cycle and for 3 days only, then hMG was
started (ultrashort the flare-up protocol)
Group D: GnRH agonist from day 21 of previous cycle and then hMG was added after
desensitisation (long protocol)
Outcomes Live birth
Pregnancy (not defined) rate per woman/cycle
Cancellation rate
Multiple pregnancy rate
Mean number of oocytes retrieved
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Kingsland 1992 (Continued)
Notes Inclusion criteria and exclusion criteria not described.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This is an RCT, however the method of random sequence gen-
eration was not described
Allocation concealment (selection bias) Unclear risk Sealed, serially numbered envelopes, however there was no men-
tion of whether they were opaque or not
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors did not state that analysis was by intention-to-treat,
however the outcomes were analysed for all participants. No
missing data or loss to follow-up was reported
Selective reporting (reporting bias) Low risk We checked a duplicate publication and there was no risk of
selective reporting
Other bias Low risk We found no other potential sources of within-study bias.
Lee 2012
Methods RCT
Country: China
Single-centre
Participants Women < 40 years undergoing IVF. History of < 4 oocytes retrieved in previous cycle
(poor responders) or < 5 AFC
Interventions Mild stimulation (n = 26): letrozole 2.5 mg from day 2 to 6 with hMG (225 IU) with
antagonist
Conventional stimulation (n = 27): hMG (225 IU) with antagonist
Outcomes Main outcomes were oocytes retrieved, clinical pregnancy rate, ongoing pregnancy rate,
and live-birth rate
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Lee 2012 (Continued)
Random sequence generation (selection
bias)
Low risk Randomised using “computer generated list”.
Allocation concealment (selection bias) Unclear risk Allocation concealment done using “opaque
sealed envelopes”; not mentioned if envelopes
were numbered
Blinding (performance bias and detection
bias)
All outcomes
Low risk Although blinding was not mentioned, we did
not consider that blinding was likely to influence
findings for our primary and secondary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomised were included in analysis.
Selective reporting (reporting bias) Low risk All the specified outcomes were reported.
Other bias Low risk We detected no other source of bias within the
study.
Lin 2006
Methods RCT
Participants 120 women undergoing their first ICSI cycle
Inclusion criteria: women aged 20 to 38 years with regular cycles, day 3 FSH < 10 mIU/
mL, BMI between 18.5 and 24.9 kg/m2, male factor infertility.
Exclusion criteria: other indications for infertility including endometriosis, anovulation,
PCOS, and hydrosalpinx
Interventions Clomiphene citrate + hMG + cetrorelix (antagonist) versus GnRHa (long) + hMG
Outcomes Live-birth rate
Clinical pregnancy (ultrasound viable foetus) rate
Cancellation rate
Implantation rate
Severe OHSS rate
Mean number of oocytes
Mean number of gonadotropins
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This an RCT, however the method of random sequence gener-
ation was not described
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Lin 2006 (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “Allocation concealment we performed through sealed
envelopes and physicians were not aware of the allocation until
the patients were about to start ovarian stimulation”; however,
there was no mention of whether or not the envelopes were
opaque or serially numbered
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised women were analysed. No missing data or loss
to follow-up was reported
Selective reporting (reporting bias) Low risk Although there was no available published protocol, all out-
comes of interest were reported
Other bias Low risk We found no other potential sources of within-study bias.
Long 1995
Methods RCT
Participants 75 patients undergoing their first IVF cycle; women were between 25 and 45 years old
Interventions CC + hMG versus GnRHa + hMG (short protocol)
Outcomes Pregnancy rate per couple
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This is an RCT, however the method of random sequence gen-
eration was not described
Allocation concealment (selection bias) Unclear risk Not mentioned in study if allocation concealment was per-
formed
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All couples that participated in the study were analysed.
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Long 1995 (Continued)
Selective reporting (reporting bias) Low risk The published protocol for this study was not available, however
most outcomes of interest were reported
Other bias Low risk We found no other potential sources of within-study bias.
Mohsen 2013
Methods RCT
Country: Egypt
Single-centre
Participants Women undergoing IVF with previous failed IVF due to poor response were included
Women with severe endometriosis, severe male factor, and history of previous pelvic or
ovarian surgery were excluded
Interventions Mild stimulation (n = 30): letrozole 2.5 mg from day 2 to 6 and hMG along with
antagonist
Conventional (n = 30): microdose flare protocol with 300 IU hMG
Outcomes Clinical pregnancy rate, cancellation rates; outcomes were not clearly mentioned
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer generated randomization”
Allocation concealment (selection bias) Unclear risk Allocation concealment done by sealed envelopes.
No other details
Blinding (performance bias and detection
bias)
All outcomes
Low risk Although blinding was not mentioned, we did
not consider that blinding was likely to influence
findings for our primary and secondary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised women were included in the anal-
ysis with no loss to follow-up
Selective reporting (reporting bias) Unclear risk Outcomes not clearly stated, and protocol not
available; not enough information to make a
judgement
Other bias Low risk We did not find any other bias in the study.
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Mukherjee 2012
Methods RCT
Country: India
Single-centre
Participants Women between 25 and 35 years of age
Normogonadotropic, without PCOS or endometriosis
Undergoing IVF for male factor (azoospermia)
Interventions Group A (42 women): letrozole 5 mg from day 3 to 7 along with recombinant FSH (75
IU) and antagonist
Group B (52 women): recombinant FSH (150 to 225 IU) and antagonist protocol
Outcomes Outcomes were total gonadotropins dose, oocytes retrieved, clinical pregnancy rate
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of random sequence generation was
not described, so we are unable to judge
Allocation concealment (selection bias) Unclear risk The method of allocation concealment is not
clearly described; only randomly divided by
“sealed envelopes”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Although trial is described as single-blinded, it was
unclear who was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All couples that participated in the studywere anal-
ysed.
Selective reporting (reporting bias) Low risk The published protocol for this study was not
available, howevermost outcomes previously spec-
ified were reported
Other bias Unclear risk We found no other potential sources of within-
study bias.
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Nabati 2016
Methods RCT
Country: Iran
Single-centre
Participants Included women who were poor responders: FSH 10 to 15 IU/mL or oestradiol < 1500
pg/mL or ultrasound with 3 follicles in previous IVF or age > 40 years
Women were excluded for endometriosis, sustained hyperprolactinaemia, FSH > 15 IU/
mL, male azoospermia, or single ovary
Interventions Mild stimulation (n = 62): letrozole 5 mg twice daily from day 2 to 6 with gonadotropins
450 IU until trigger versus microdose flare protocol (n = 61) with gonadotropins 300
IU
Outcomes gonadotropins consumption, number of days stimulation, number of oocytes retrieved,
and clinical pregnancy rate per woman randomised
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Design stated in title and abstract, however ran-
domisation method not mentioned
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Ultrasound personnel and embryologist blinded.
However, we did not consider blinding to influence
the primary and secondary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up not mentioned, however inten-
tion-to-treat analysis was done
Selective reporting (reporting bias) Low risk Outcomes not clearly stated in methods section,
however registered trial and all stated outcomes have
been reported
Other bias Low risk We identified no potential source of bias within the
study.
Pilehvari 2016
Methods RCT
Country: Iran
Single-centre
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Pilehvari 2016 (Continued)
Participants Poor responder according to Bologna criteria, 2 out of 3 criteria: advanced maternal age
≥ 40 years or previous poor response < 3 oocytes or AFC 5 to 7 or AMH < 0.5 -1.1 ng/
mL
Exclusion criteria: use of any infertility medicine in the previous 3 months and “presence
of any medical history”
Interventions Group 1 (n = 42): mild stimulation, clomiphene 100 mg from day 2 for 5 days with
hMG 150 IU/day from day 5 with antagonist
Group 2 (n = 35): conventional protocol, gonadotropins (hMG/recombinant FSH) 300
IU/day with antagonist
Outcomes Clinican pregnancy rate, days of stimulation, number of oocytes, cancellation rate
Other outcomes not included in review: fertilisation rate, endometrial thickness
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias)
All outcomes
Low risk Although blinding was not mentioned, we did not
consider that blinding was likely to influence the
findings for our primary and secondary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised women were analysed. No loss to
follow-up.
Selective reporting (reporting bias) Low risk All the outcomes mentioned in methods section
were reported.
Other bias Low risk No funding.We identifiednoother potential source
of bias.
Ragni 2012
Methods RCT
Country: Italy
Recruitment: patients referring to 4 infertility units in Milan, Rozzano, and Monza in
Italy and selected for IVF were evaluated for study entry
Participants 304 women with day 3 serum FSH > 12 IU/mL on at least 2 occasions or previous poor
response to hyperstimulation.
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Ragni 2012 (Continued)
Inclusion criteria: 1) indication to IVF-ICSI; 2) age 18 to 42 years; 3) day 3 serum
FSH > 12 IU/mL on at least 2 occasions or previous poor response (≤ 3 oocytes with a
conventional stimulation protocol) in a previous IVF cycle.
Exclusion criteria: 1) number of previous IVF cycles≥ 3; and 2) cycles requiring the use
of spermatozoa from MESA-TESE procedures
Interventions Group 1 (n = 148): clomiphene citrate oral tablets 150 mg/day from day 3 to 7 of the
cycle
Group 2 (n = 156): daily s.c. injections of triptorelin (GnRH agonist) started on day 1
or 2 of the menstrual cycle and 450 IU of s.c. recombinant FSH from day 3 of the cycle,
short protocol
Outcomes Live birth per women randomised, clinical pregnancy rate, cycle cancellation rate, mul-
tiple pregnancy rate, rate of foetal abnormalities
Other outcomes not included in review: number of follicles > 15 mm; number of follicles
> 10 mm; number of oocytes retrieved; fertilisation rate; number of women who under-
went embryo transfer; number of embryos transferred; implantation rate; any adverse
events; costs
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomised by means of a computer-gen-
erated list into two groups”
Allocation concealment (selection bias) Unclear risk “Sealed opaque envelopes containing treat-
ment allocation were opened after inclu-
sion”; not mentioned if envelopes were
numbered
Blinding (performance bias and detection
bias)
All outcomes
Low risk Although this study was not blinded, we
did not consider that lack of blinding was
likely to influence the findings for our pri-
mary and secondary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up was reported and reasons
given.The numberswere balanced between
groups. An intention-to-treat analysis was
done
Selective reporting (reporting bias) Low risk The proposed outcomes in the ClinicalTri-
als.gov registration (NCT01389713) were
reported in the paper publication
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Ragni 2012 (Continued)
Other bias High risk The study was interrupted after the sched-
uled 2 years of recruitment before reach-
ing the sample size, leaving the study power
at 60% instead of the planned 80%. One
of the reasons for premature closure of the
trial was slow recruitment
Revelli 2014
Methods RCT
Country: Italy
Recruitment: participants were recruited from those undergoing IVF who were classified
as expectant poor responders
Participants 695 women with clinical, endocrine, and ultrasound characteristics suggesting a low
ovarian reserve and a poor responsiveness to COH. Each woman was included in the
study for only 1 IVF cycle
Inclusion criteria: 1) circulating menstrual cycle day 3 FSH between 10 and 20 IU/L in
the presence of oestradiol (E2) serum level < 80 pg/mL; 2) circulating AMH between 0.
14 and 1.0 ng/mL; 3) antral follicle count assessed by transvaginal ultrasound of between
4 and 10
Exclusion criteria: women with basal FSH > 20 IU/L; undetectable AMH levels; AFC <
3; and age over 43 years
Interventions “Mild” protocol (n = 355): clomiphene citrate 100 mg/day for 5 days from the 2nd
to 6th day of the menstrual cycle + low-dose 150 IU/day of subcutaneously injected
gonadotropins + GnRH antagonist from the 8th day of the cycle until the day of hCG
administration
“Long” protocol (n = 340): 0.8 mg/day GnRH agonist given intranasally from the 21st
day of the run-in cycle for 14 days and at the beginning of gonadotropins administra-
tion; the dose was reduced to 0.4 mg/day and continued during ovarian stimulation.
Exogenous gonadotropins were administered at a starting daily dose of 300 IU, which
was eventually increased up to a maximum of 450 IU/day after 1 week
Outcomes Mean number of oocytes retrieved, cycle cancellation rate, total administered go-
nadotropins dose; length of ovarian stimulation, clinical (ultrasound-confirmed) preg-
nancy rate per started cycle, miscarriage rate, ongoing pregnancy rate at 12 weeks’ ges-
tational age
Other outcomes reported in study but not entered into review: fertilisation rate, implan-
tation rate, pregnancy rate per oocyte pick-up and per embryo transfer
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Revelli 2014 (Continued)
Random sequence generation (selection
bias)
Low risk “Randomization was performed using a
computerized algorithm without any re-
striction. No blocks were used since the size
of the study group was estimated to be large
enough to ensure a balanced distribution
of patients between groups”
Allocation concealment (selection bias) Low risk “Allocation concealment was obtained us-
ing sequentially numbered dark envelopes:
until they were opened at the time of allo-
cation, both physicians and patients were
blinded to the study.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk There was no description in the trial report
of blinding participants or personnel after
allocation was completed. However, we did
not consider that potential lack of blinding
was likely to influence the findings for our
primary and secondary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up after randomisation
was reported. The “loss to follow up” term
used in the report indicated the cancelled
cycle due to poor response, which is ex-
pected in poor responder population
Selective reporting (reporting bias) Low risk Every outcome proposed in the methods
was explored. However, the study protocol
was not available
Other bias Low risk We found no other potential sources of
within-study bias.
Schimberni 2016
Methods RCT
Country: Italy
Single-centre
Participants Women meeting at least 2 of the following criteria were defined as poor responders:
1) age > 40 years; 2) basal FSH > 12 mIU/ mL; 3) 3 or fewer oocytes retrieved in the
previous IVF cycle; 4) low oestradiol levels on the day of hCG administration (< 1500
pmol/mL)
Exclusion criteria: women with a BMI > 30; biochemical and ultrasound evidence of
polycystic ovary syndrome; stage III-IV endometriosis; inflammatory, autoimmune, or
metabolic disorders; infertility medications (gonadotropins, clomiphene citrate) taken
within the past 2 months
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Schimberni 2016 (Continued)
Interventions Group 1 (n = 78) mild stimulation: clomiphene citrate 100 mg from day 2 for 5 days
and FSH 450 IU/day from day 5 with antagonist
Group 2 (n = 78): FSH 450 IU/day with antagonist.
Group 3 (n = 78): FSH 450 IU/day with short agonist protocol
Outcomes Clinical pregnancy rate, implantation rate, days of stimulation, mature oocytes retrieved
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation; block ran-
domisation done
Allocation concealment (selection bias) Unclear risk Study mentions blinding of study team to allotted
group, but does not describe actual method used
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding not mentioned, however we did not con-
sider that potential lack of blinding was likely to in-
fluence the findings for our primary and secondary
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants randomised and loss to follow-
up were mentioned and appeared to be balanced.
However, intention-to-treat analysis not done
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported.
Other bias Low risk Funding not mentioned. We identified no other
potential source of bias
Tummon 1992
Methods RCT
Participants 508 couples undergoing their first IVF cycle were randomised into 2 groups. However,
only 408 couples initiated treatment
Inclusion criteria: any type of infertility that indicates IVF
Exclusion criteria: couples in whom the sperm count was less than 100,000 motile
spermatozoa
Interventions Group A: clomiphene citrate + hMG
Group B: GnRHa + hMG (long protocol)
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Tummon 1992 (Continued)
Outcomes Pregnancy rate
Implantation rate
Cancellation rate
Mean number of oocytes
Mean number of gonadotropins
Notes 17% of couples assigned to Group A dropped out after randomisation and before start
of treatment, while 23% of couples in Group B dropped out after randomisation and
before start of treatment. Reasons were not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A sequence of randomisation numbers
Allocation concealment (selection bias) Unclear risk The method of allocation concealment was not mentioned.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
High risk No intention-to-treat analysis and the analysis was per cycle.
Loss to follow-up and dropout rates were large and reasons were
not clearly specified
Selective reporting (reporting bias) Low risk Although live-birth rate was not reported, most secondary out-
comes were reported
Other bias Low risk We found no other potential sources of within-study bias.
Weigert 2002
Methods RCT
Participants 294 infertile women undergoing IVF-embryo transfer
Inclusion criteria: first IVF cycle; women between 20 and 39 years of age; normal ovula-
tory cycles; tubal infertility,male factor, or unexplained infertility; early stage endometrio-
sis
Exclusion criteria: women with chronic medical diseases, contraindication or allergy to
the study medications, irregular cycles, low or high BMI (< 20 or > 30 kg/m2), or baseline
FSH level > 15 IU/L.
Interventions Clomiphene citrate + rFSH + rLH + prednisolone (Group A) versus long GnRH agonist
suppression + rFSH (long protocol) (Group B)
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Weigert 2002 (Continued)
Outcomes Pregnancy rate, cancellation rate, OHSS rate, fertilisation rate, implantation rate, mean
number of gonadotropins, mean number of oocytes
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list
Allocation concealment (selection bias) Unclear risk The method of allocation concealment was not mentioned.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not mentioned; not enough information to make
a judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No intention-to-treat analysis and the analysis was per cycle. No
clear mention of loss to follow-up
Selective reporting (reporting bias) Low risk Although live-birth rate was not reported, most secondary out-
comes were reported
Other bias Low risk We found no other potential sources of within-study bias.
Youssef 2011
Methods RCT
Participants 70 women undergoing IVF treatment
Inclusion criteria: women aged 20 to 42 years with a history of 1- or 2-year infertility
were included. Poor response was defined by the number of dominant follicles on hCG
day and number of mature oocytes < 3 or cycle cancellation due to poor ovarian response
Interventions Study group (35 women): clomiphene citrate + hMG + midcycle antagonist
Control group (35 women): GnRH agonist + hMG (long protocol)
Outcomes Pregnancy rate
Cancellation rate
Mean number of oocytes
Mean number of gonadotropins
Notes We have categorised this study as poor responders as mentioned in the abstract after
analysing the data and outcomes (e.g. mean oocytes retrieved)
Risk of bias
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Youssef 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk This is an RCT in which random sequence was computer gen-
erated
Allocation concealment (selection bias) Unclear risk Sealed envelopes (there was no mention of whether they were
opaque or not)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Although blinding was not mentioned, we acknowledge that
participant blinding is not possible for this type of comparison
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were analysed per woman randomised. No loss to follow-
up was reported
Selective reporting (reporting bias) Low risk The reported outcomes were similar to those published in the
protocol
Other bias Low risk We found no other potential sources of within-study bias.
AFC: antral follicle count
AMH: anti-Müllerian hormone
ART: assisted reproductive technology
BMI: body mass index
CC: clomiphene citrate
COH: controlled ovarian stimulation
DHEA: dehydroepiandrosterone
FSH: follicle-stimulating hormone
GnRH: gonadotropin-releasing hormone
GnRHa: gonadotropin-releasing hormone agonist
hCG: human chorionic gonadotropin
hMG: human menopausal gonadotropin
HSG: hysterosalpingogram
LH: luteinising hormone
ICSI: intracytoplasmic sperm injection
IVF: in vitro fertilisation
MESA-TESE: microsurgical epididymal sperm aspiration-testicular excisional sperm extraction
OHSS: ovarian hyperstimulation syndrome
PCOS: polycystic ovary syndrome
POR: poor ovarian reserve
RCT: randomised controlled trial
rFSH: recombinant follicle-stimulating hormone
rLH: recombinant luteinising hormone
s.c.: subcutaneous
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdalla 1990 A quasi-randomised trial, as participants were randomised into 1 of 2 groups
according to the day of their first consultation
Cassidenti 1992 The population was not infertile women but women undergoing ovarian
hyperstimulation for the sole purpose of oocytes donation
Dhont 1995 Participants may have had either GIFT or IVF, and it was not possible to
separate the outcomes of the 2 forms of assisted reproduction
Engel 2002 Non-randomised trial
Ferraretti 2015 A cohort study
Ferrier 1990 Participants may have had either GIFT or IVF and the results were analysed
per cycle, and it was not possible to obtain the results per woman randomised
Fiedler 2001 Inappropriate comparison: both arms compared CC + hMGwith and with-
out antagonist
Ghanem 2013 Participants were not undergoing IVF or ICSI.
Goldman 2014 Inappropriate comparison: included IUI versus IVF treatments
Gonen 1990 Unclear whether study had a randomised trial design
Ibrahim 2012 Participants were not undergoing IVF or ICSI.
Imoedemhe 1987 Inappropriate comparison: all 3 groups used CC initially.
Karimzadeh 2011 Control arm inappropriate.
Kim 2000 Unclear whether study had a randomised trial design. We could not contact
author due to lack of contact information
Kubik 1990 A quasi-randomised method (alternating method). This study was included
in a previous meta-analysis by Hughes 1992, and the author of the meta-
analysis obtained information about the randomisation method from the
authors of the trial
Legro 2012 Participants were not undergoing IVF or ICSI.
Liu 2016 Did not have fresh embryo transfer
Macnamee 1989 A quasi-randomised trial
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(Continued)
Martinez 2003 Inappropriate comparison: comparing short versus antagonist protocol
Nagulapally 2012 Inappropriate comparison: study compared clomiphenewith gonadotropins
versus letrozole with gonadotropins
Nahid 2012 Participants were not undergoing IVF or ICSI.
Nakajo 2011 Inappropriate comparison: study compared clomiphenewith gonadotropins
versus letrozole with gonadotropins
NCT01577199 Protocol was withdrawn before recruitment.
NCT01577472 Participants were not undergoing IVF or ICSI.
NCT01679574 Participants were not undergoing IVF or ICSI.
NCT01718444 Participants were not undergoing IVF or ICSI.
NCT01791751 Study evaluated use of CC in luteal phase on LH levels.
NCT01856062 Participants were not undergoing IVF or ICSI.
NIH/NICHD Reproductive Medicine Network 2013 Participants were not undergoing IVF or ICSI.
Oktem 2015 Not randomised
Oride 2015 Not randomised
Quigley 1984 Inappropriate comparison: compared CC versus CC with gonadotropins
Reindollar 2011 Not all participants were undergoing IVF or ICSI.
Rose 2015 Not randomised
Roy 2012 Participants were not undergoing IVF or ICSI.
Sharma 2014 Not randomised
Shelton 1991 Non-randomised trial, as allocation was intentionally by 2 clinicians acting
independently without randomisation
Siristatidis 2016 Quasi-randomised trial
Wagman 2010 Participants were not undergoing IVF or ICSI.
Ye 2016 Did not have fresh embryo transfer
63Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women
undergoing in vitro fertilisation (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Zhang 2014 Did not have fresh embryo transfer in the minimal-stimulation group
CC: clomiphene citrate
GIFT: gamete intrafallopian transfer
hMG: human menopausal gonadotropin
ICSI: intracytoplasmic sperm injection
IUI: intrauterine insemination
IVF: in vitro fertilisation
LH: luteinising hormone
Characteristics of ongoing studies [ordered by study ID]
NCT 01921166
Trial name or title Maximal stimulation and delayed fertilization for diminished ovarian reserve: a randomized pilot study
Methods Open-label RCT
Participants Women with a poor prognosis due to diminished ovarian reserve
Inclusion criteria: basal FSH 17 IU/mL (highest ever); basal FSH 15 to 17 (highest ever), and failed EFORT
test; age > 43 at the time of expected retrieval; failure to conceive with a prior “poor prognosis” IVF stimula-
tion protocol (microdose leuprolide flare or GnRH antagonist cycle) if administered because of evidence of
diminished ovarian reserve; failure to conceive with 3 or more IVF cycles at Carolinas Medical Centre (CMC)
Exclusion criteria: contraindications to IVF; contraindication to pregnancy; allergy or contraindication to
medications used for IVF or embryo transfer; use for a gestational carrier; uncorrected or untreatable uterine
infertility; smoking or substance abuse within 3 months of initiating stimulation for IVF
Interventions Clomiphene plus gonadotropins
Leuprolide flare
Outcomes Number of oocytes retrieved; number of oocytes vitrified; number of embryos from vitrified oocytes per
ovarian stimulation treatment protocol
Starting date January 2011
Contact information Brad Hurst, Director, Assisted Reproductive Therapies, Carolinas Healthcare System
Notes The status of the study in the registry is completed. We emailed contact person; authors responded with
incomplete data that could not be pooled
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NCT 01948804
Trial name or title The comparisonof effect of four different treatment protocols on IVFoutcomes in poor responders undergoing
in vitro fertilization
Methods Double-blind RCT
Participants Poor responders undergoing in vitro fertilisation
Inclusion criteria: at least 1 of the following:
• anti-Müllerian hormone < 1.1 ng/mL or a previous poor ovarian response (≤ 3 oocytes with a
conventional stimulation protocol), or both;
• primary infertile patients;
• BMI ≤ 30 kg/m2.
Interventions GnRH antagonist/letrozole protocol
Microdose flare-up protocol
Antagonist/clomiphene protocol
GnRH antagonist protocol
Outcomes Clinical pregnancy rates; total number of oocytes retrieved
Starting date January 2014
Contact information P nar Özcan Cenksoy, Medical Doctor, Yeditepe University Hospital
Notes We emailed contact person, have as yet received no response.
NCT 02237755
Trial name or title Clomiphene citrate in combination with gonadotropins for ovarian stimulation in women with poor ovarian
response
Methods Single-blind RCT
Participants Women with poor response to ovarian stimulation. The definition of poor response was based on the presence
of at least 1 of the following criteria:
• age > 40 years;
• day 2 FSH > 9.5 mIU/mL;
• AMH < 2 ng/mL;
• at least 1 previous COH with < 3 oocytes retrieved;
• at least 1 cancelled attempt due to poor response;
• oestradiol less than 500 pg/mL on the day of hCG.
Interventions Clomiphene citrate: clomiphene citrate (100 mg/day) in combination with gonadotropins according to a
short stimulation GnRH antagonists protocol
Gonadotropins: short stimulation protocol with gonadotropins and GnRH antagonists
All women will be stimulated with a fixed GnRH antagonist protocol. Ovarian stimulation will be initiated
with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH
or with a combination of rFSH and rLH
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NCT 02237755 (Continued)
Outcomes Clinical pregnancy
Starting date October 2014
Contact information Nikos Vlahos, MD, University of Athens, 2nd Department of Obstetrics and Gynecology, nikosvlahos@med.
uoa.gr
Notes We contacted the author but have received no response.
NCT 02912988
Trial name or title Letrozole in stimulated IVF cycles
(A randomized trial of letrozole as an adjunct to follicle stimulating hormone in stimulated in vitro fertilization
cycles)
Methods RCT
Participants 900
Interventions Experimental: Letrozole group: letrozole + standard treatment: daily 150 to 300 IU hMG/FSH from cycle day
2 to 4 (at least 5 days after stopping the oral contraceptive pill) and cotreatment with letrozole 2.5 mg daily
from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrorelix (Cetrotide)
or ganirelix (Orgalutran)) 0.25 mg daily from stimulation day 5 until the day of hCG administration
Control group: Standard treatment: daily 150 to 300 IU hMG/FSH cycle day 2 to 4 (at least 5 days after
stopping the oral contraceptive pill) until the day before hCG administration. GnRH antagonist 0.25 mg
daily from stimulation day 5 until the day of hCG administration
Outcomes • Miscarriage rate
• Clinical and ongoing pregnancy rates
• Ovarian hyperstimulation rate
• Total IU of FSH used per cycle
• Number of follicles > 12 mm on day of hCG (or the day before)
• Number of oocytes obtained
• Number of oocytes obtained during the operation of transvaginal ultrasound-guided oocyte retrieval
• Oocyte fertilisation rate
• Number and quality of embryos obtained
• Endometrial thickness on day of hCG (or the day before)
• Serum oestradiol level on day of hCG administration (or the day before)
• Hormonal profile on day of hCG administration (or the day before): serum oestradiol level
• Serum progesterone levels on day of hCG administration (or the day before)
• Serum testosterone levels on day of hCG administration (or the day before)
• Hormonal profile on day of hCG administration (or the day before): serum testosterone level
• Follicular fluid hormonal profile: inhibin B level, testosterone and AMH level
• Complications of pregnancy: small for gestational age, low birth weight, preterm delivery, pre-
eclampsia, antepartum haemorrhage, congenital anomaly, perinatal mortality, multiple pregnancy
Starting date November 2016
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NCT 02912988 (Continued)
Contact information Ernest HY Ng, MD, nghye@hku.hk
Notes Multicentre trial:
• The University of Hong Kong
• University of Southampton
• Peking University Third Hospital
• Chinese PLA General Hospital
AMH: anti-Müllerian hormone
BMI: body mass index
COH: controlled ovarian stimulation
EFORT: exogenous follicle-stimulating hormone ovarian reserve
FSH: follicle-stimulating hormone
GnRH: gonadotropin-releasing hormone
hCG: human chorionic gonadotropin
hMG: human menopausal gonadotropin
IVF: in vitro fertilisation
LH: luteinising hormone
RCT: randomised controlled trial
rFSH: recombinant follicle-stimulating hormone
rLH: recombinant luteinising hormone
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D A T A A N D A N A L Y S E S
Comparison 1. Clomiphene citrate or letrozole with or without gonadotropins in conjunction with or without
midcycle antagonist versus gonadotropins (with GnRH agonists or midcycle antagonist) in IVF and ICSI cycles in
general population
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth 4 493 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.66, 1.27]
1.1 Clomiphene citrate ±
gonadotropins ± antagonist vs.
agonist protocol
4 493 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.66, 1.27]
1.2 Clomiphene citrate ±
gonadotropins ± antagonist vs.
antagonist protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Letrozole ± gonadotropins
± antagonist vs. agonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Letrozole ± gonadotropins
± antagonist vs. antagonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Ovarian hyperstimulation
syndrome
5 1067 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.21 [0.11, 0.41]
2.1 Clomiphene citrate ±
gonadotropins ± antagonist vs.
agonist protocol
4 973 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.23 [0.11, 0.47]
2.2 Clomiphene citrate ±
gonadotropins ± antagonist vs.
antagonist protocol
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Letrozole ± gonadotropins
± antagonist vs. agonist
protocol
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Letrozole ± gonadotropins
± antagonist vs. antagonist
protocol
1 94 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.14 [0.03, 0.68]
3 Ongoing pregnancy rate 6 758 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.77, 1.30]
3.1 Clomiphene citrate ±
gonadotropins ± antagonist vs.
agonist protocol
6 758 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.77, 1.30]
3.2 Clomiphene citrate ±
gonadotropins ± antagonist vs.
antagonist protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Letrozole ± gonadotropins
± antagonist vs. agonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Letrozole ± gonadotropins
± antagonist vs. antagonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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4 Clinical pregnancy rate 12 1998 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.86, 1.16]
4.1 Clomiphene citrate ±
gonadotropins ± antagonist vs.
agonist protocol
9 1784 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.88, 1.23]
4.2 Clomiphene citrate±
gonadotropins ± antagonist vs.
antagonist protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Letrozole ± gonadotropins
± antagonist vs. agonist
protocol
1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.12, 0.72]
4.4 Letrozole ± gonadotropins
± antagonist vs. antagonist
protocol
2 134 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.71, 1.94]
5 Cancellation rate 9 1784 Risk Ratio (M-H, Fixed, 95% CI) 1.87 [1.43, 2.45]
5.1 Clomiphene citrate ±
gonadotropins ± antagonist vs.
agonist protocol
9 1784 Risk Ratio (M-H, Fixed, 95% CI) 1.87 [1.43, 2.45]
5.2 Clomiphene citrate ±
gonadotropins ± antagonist vs.
antagonist protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Letrozole ± gonadotropins
± antagonist vs. agonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Letrozole ± gonadotropins
± antagonist vs. antagonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Mean number of ampoules used 6 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Clomiphene citrate ±
gonadotropins ± antagonist vs.
agonist protocol
6 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Clomiphene citrate ±
gonadotropins ± antagonist vs.
antagonist protocol
0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Letrozole ± gonadotropins
± antagonist vs. agonist
protocol
0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Letrozole ± gonadotropins
± antagonists vs. antagonist
protocol
0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Mean number of oocytes
retrieved
8 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Clomiphene citrate ±
gonadotropins ± antagonist vs.
agonist protocol
8 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Clomiphene citrate ±
gonadotropins ± antagonist vs.
antagonist protocol
0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Letrozole ± gonadotropins
± antagonists vs agonist
protocol
0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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7.4 Letrozole ± gonadotropins
± antagonist vs. antagonist
protocol
0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Multiple pregnancy rate 5 791 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.39, 1.43]
8.1 Clomiphene citrate ±
gonadotropins ± antagonist vs.
agonist protocol
4 697 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.40, 1.57]
8.2 Clomiphene citrate ±
gonadotropins ± antagonist vs.
antagonist protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Letrozole ± gonadotropins
± antagonist vs. agonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.4 Letrozole ± gonadotropins
± antagonist vs. antagonist
protocol
1 94 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.04, 3.82]
9 Rate of miscarriage 7 1116 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.61, 1.47]
9.1 Clomiphene citrate ±
gonadotropins ± antagonists vs.
agonist protocol
6 1022 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.61, 1.75]
9.2 Clomiphene citrate ±
gonadotropins ± antagonists vs.
antagonist protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Letrozole ± gonadotropins
± antagonist vs. agonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.4 Letrozole ± gonadotropins
± antagonists vs. antagonists
protocol
1 94 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.35, 1.66]
10 Rate of ectopic pregnancy 2 223 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.56 [0.47, 120.94]
10.1 Clomiphene citrate ±
gonadotropins ± antagonist vs.
agonist protocol
2 223 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.56 [0.47, 120.94]
10.2 Clomiphene citrate ±
gonadotrophins ± antagonists
vs. antagonist protocol
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 Letrozole ±
gonadotropins ± antagonists vs.
agonists protocol
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.4 Letrozole ±
gonadotropins ± antagonists vs.
antagonist protocol
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Rate of foetal abnormalities 1 74 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.1 Clomiphene citrate ±
gonadotropins ± antagonists vs.
GnRHagonists or antagonist
protocol
1 74 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 Letrozole ±
gonadotropins ± antagonists vs.
GnRH agonist or antagonist
protocol
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 2. Clomiphene citrate or letrozole with or without gonadotropins in conjunction with or without
midcycle antagonist versus gonadotropins (with GnRH agonist or midcycle antagonist) in IVF and ICSI cycles in
poor responders
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth 2 357 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.49, 2.79]
1.1 Clomiphene citrate ±
gonadotropin ± antagonist vs.
agonist protocol
1 304 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.24, 2.32]
1.2 Clomiphene citrate ±
gonadotrophin ± antagonists
vs. antagonist protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Letrozole ± gonadotrophin
± antagonist vs. agonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Letrozole ± gonadotropin
± antagonist vs. antagonist
protocol
1 53 Risk Ratio (M-H, Fixed, 95% CI) 2.60 [0.55, 12.22]
2 Ongoing pregnancy rate 2 748 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.58, 1.28]
2.1 Clomiphene citrate ±
gonadotropin ± antagonist vs.
agonist protocol
1 695 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.52, 1.19]
2.2 Clomiphene citrate ±
gonadotrophin ± antagonists
vs. antagonist protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Letrozole ± gonadotrophin
± antagonists vs. agonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Letrozole ± gonadotropin
± antagonists vs. antagonist
protocol
1 53 Risk Ratio (M-H, Fixed, 95% CI) 2.60 [0.55, 12.22]
3 Clinical pregnancy rate 8 1462 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.64, 1.12]
3.1 Clomiphene citrate ±
gonadotropins ± antagonist vs.
agonist protocol
3 1069 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.66, 1.27]
3.2 Clomiphene citrate ±
gonadotrophin ± antagonists
vs. antagonists protocol
1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.05, 12.84]
3.3 Letrozole ± gonadotropin
± antagonists vs. agonists
protocol
3 221 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.29, 1.13]
3.4 Letrozole ± gonadotropin
± antagonists vs. antagonists
protocol
1 95 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.38, 2.86]
4 Cancellation rate 10 1601 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [1.18, 1.81]
4.1 Clomiphene citrate ±
gonadotropin ± antagonist vs.
agonist protocol
4 1155 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [1.20, 2.10]
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4.2 Clomiphene citrate ±
gonadotropin ± antagonists vs.
antagonists protocol
1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.39, 1.53]
4.3 Letrozole ± gonadotropin
± antagonist vs. agonists
protocol
3 221 Risk Ratio (M-H, Fixed, 95% CI) 1.86 [1.10, 3.13]
4.4 Letrozole ± gonadotropin
± antagonists vs. antagonists
protocol
2 148 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.67, 2.01]
5 Mean number of ampoules used 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Clomiphene citrate ±
gonadotropin ± antagonists vs.
agonist protocol
2 87 Mean Difference (IV, Fixed, 95% CI) -23.98 [-27.41, -20.
56]
5.2 Clomiphene citrate ±
gonadotrophin ± antagonist vs.
antagonist protocol
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Letrozole ± gonadotropin
± antagonist vs. agonist
protocol
1 49 Mean Difference (IV, Fixed, 95% CI) -46.24 [-50.93, -41.
55]
5.4 Letrozole ± gonadotrophin
± antagonist vs. antagonist
protocol
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Mean number of oocytes
retrieved.
8 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Clomiphene citrate ±
gonadotropin ± antagonists vs.
agonist protocol
4 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Clomiphene citrate ±
gonadotropin ± antagonist vs.
antagonist protocol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Letrozole ± gonadotropin
± antagonists vs. agonist
protocol
3 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Letrozole ± gonadotropin
± antagonists vs. antagonist
protocol
0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Multiple pregnancy rate 1 304 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.05, 5.75]
7.1 Clomiphene citrate ±
gonadotropin ± antagonist vs.
agonist protocol
1 304 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.05, 5.75]
7.2 Clomiphene citrate ±
gonadotrophin ± antagonist vs.
antagonist protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Letrozole ± gonadotrophin
± antagonist vs. agonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 Letrozole ± gonadotrophin
± antagonist vs. antagonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Rate of miscarriage 3 818 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.45, 2.12]
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8.1 Clomiphene citrate ±
gonadotropin ± antagonists vs.
agonist protocol
2 765 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.55, 3.01]
8.2 Clomiphene citrate ±
gonadotrophin ± antagonist vs.
antagonist protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Letrozole ± gonadotrophin
± antagonist vs. agonist
protocol
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.4 Letrozole ± gonadotropin
± antagonists vs. antagonist
protocol
1 53 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 2.73]
A D D I T I O N A L T A B L E S
Table 1. Cycle characteristics of the included trials
Study ID Downregula-
tion used
Type of FSH
used
Starting dose
of FSH
Dose of
clomiphene
citrateor
letrozole
Cycle moni-
toring
Luteal
support
Timing of
hCG
Ashrafi 2005 Buserelin hMG 150 to 225
IU/day
100 mg CC Ultrasound Progesterone Leading folli-
cle 17 mm
Bastu 2016 Antago-
nist (cetrorelix
subcutaneous)
hMG and re-
combinant
FSH
hMG and re-
combi-
nant FSH but
in different
doses:
Group 1: 225
IU hMG +
225 IU rFSH
Group 2: 150
IU hMG +
150 IU rFSH
Group 3: 5mg
Ltz + 150 IU
rFSH
5 mg Ltz Ultrasound Progesterone Leading folli-
cle > 17 mm
Elnashar 2016 Antagonist
(ganirelix (Or-
galutran) sub-
cutaneous) for
the Ltz group
and triptorelin
subcutaneous
in the agonist
control group
FSH 75 IU for the
Ltz group ver-
sus 150 to
225 IU for the
control FSH/
agonist group
10 mg Ltz Not
mentioned
Not
mentioned
Not
mentioned
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Table 1. Cycle characteristics of the included trials (Continued)
Fenichel 1988 Triptorelin in-
tramuscular
hMG hMG 125 to
300 IU/day
200 mg CC Ultrasound
and oestradiol
hCG Leading folli-
cle 17 mm
Fujimoto
2014
Ganirelix hMG Not
mentioned
100 mg CC Not
mentioned
Not
mentioned
Not
mentioned
Galal 2012 Not
mentioned
hMG 150 to 225 IU 10 mg Ltz Not
mentioned
Not
mentioned
Not
mentioned
Ghosh
Dastidar 2010
Not
mentioned
Recombinant
FSH
100 to 150 IU
in
the CC + go-
nadotropins
group; 200 to
225 IU in the
go-
nadotropins
+ GnRH ago-
nist group)
Not
mentioned
Not
mentioned
Not
mentioned
Not
mentioned
Grochowski
1999
Triptorelin in-
tramuscular
depot
hMG 150 to 225
IU/day
100 mg CC Ultrasound
and oestradiol
Progesterone Leading folli-
cle 18 mm
Harrison
1994
Triptorelin in-
tramuscu-
lar and busere-
lin intranasal
hMG 150 IU/day 100 mg CC Ultrasound
and oestradiol
Progesterone Leading folli-
cle 17 mm
Jindal 2013 Antago-
nist (cetrorelix
subcutaneous)
for the Ltz or
CC group and
GnRH
agonist for the
control group,
type not men-
tioned
Not
mentioned
Not
mentioned
Not
mentioned
Not
mentioned
Not
mentioned
Not
mentioned
Jutras 1991 Leuprorelin hMG 150 IU/day 50 mg CC Ultrasound
and oestradiol
Not
mentioned
Leading folli-
cle 15 mm
Karimzadeh
2010
Buserelin Recombinant
FSH
150 to 225
IU/day
100 mg CC Ultrasound Progesterone Leading folli-
cle 18 mm
Kingsland
1992
Buserelin
nasal spray
hMG According to
age (225 IU
for women <
100 mg CC Ultrasound
and oestradiol
hCG Leading folli-
cle 17 mm
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Table 1. Cycle characteristics of the included trials (Continued)
35 years and
300 IU for
women > 35
years)
Lee 2012 Antago-
nist (cetrorelix
subcutaneous)
hMG 225 IU 2.5 mg Ltz Ultrasound
and oestradiol
Progesterone Leading folli-
cle 18 mm
Lin 2006 Antago-
nist (cetrorelix
subcutaneous)
hMG 150 to 300
IU/day
100 mg CC Ultrasound,
serum oestra-
diol, LH, and
progesterone
Progesterone Leading folli-
cle 18 mm
Long 1995 Leuprorelin
(Lupron)
hMG 150 IU/day 50 mg CC Ultrasound
and oestradiol
None Leading folli-
cle 15 mm
Mohsen 2013 Antago-
nist (cetrorelix
subcuta-
neous) for the
Ltz group and
agonist (le-
uprorelin) for
the con-
ventional ago-
nist group
hMG 150 IU for the
Ltz group ver-
sus 300 IU
for the con-
trol hMG/ag-
onist group
2.5 mg Ltz Ultrasound
and oestradiol
Progesterone 18 mm
Mukherjee
2012
Antagonist
(ganirelix (Or-
galutran) sub-
cutaneous)
Recombinant
FSH
75 IU for the
Ltz group ver-
sus
150 to 225 IU
for the con-
trol FSH/an-
tagonist group
5 mg Ltz Ultrasound
and oestradiol
Progesterone 18 mm
Nabati 2016 The type of
antagonist
used was not
mentioned in
the study
while the ag-
onist used in
the con-
trol group was
buserelin
Recombinant
FSH
300 IU for the
Ltz group ver-
sus 450 IU
for the con-
trol FSH/ago-
nist group
5 mg Ltz Ultrasound Progesterone 17 mm
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Table 1. Cycle characteristics of the included trials (Continued)
Pilehvari 2016 Antago-
nist (cetrorelix
subcutaneous)
hMG 150 IU for the
CC group ver-
sus 300 IU
for the con-
trol hMG/an-
tagonist group
100 mg CC Ultrasound Progesterone 17 to 18 mm
Ragni 2012 Buserelin Recombinant
FSH
450 IU 150 mg CC Ultrasound
and oestradiol
Progesterone 18 to 20 mm
Revelli 2014 Antagonist
(cetrorelix or
ganirelix (Or-
galutran) sub-
cutaneous);
agonist was le-
uprorelin
hMG 150 IU for the
CC group ver-
sus
300 to 450 IU
for the con-
trol hMG/an-
tagonist group
100 mg CC Ultrasound
and oestradiol
Progesterone 18 to 20 mm
Schimberni
2016
Antago-
nist (cetrorelix
subcutaneous)
Recombinant
FSH
450 IU for
both groups
100 mg CC Ultrasound
and oestradiol
Progesterone 18 mm
Tummon
1992
Leuprorelin
subcutaneous
hMG According to
body weight
(less than 52
kg would start
with 75 IU/
day, 52 to 75
kg would start
with
112.5 IU/day,
and 150 IU/
day for
women who
weighed more
than 75 kg)
100 mg CC Ultrasound
and oestradiol
Progesterone Leading folli-
cle 16 mm
Weigert 2002 Buserelin Recombinant
FSH
150 IU/day 100 mg Ultrasound Progesterone Leading folli-
cle 18 mm
Youssef 2011 Buserelin hMG 225 to 300
IU/day
100 mg Ultrasound Progesterone Not
mentioned
CC: clomiphene citrate
FSH: follicle-stimulating hormone
GnRH: gonadotropin-releasing hormone
hCG: human chorionic gonadotropin
hMG: human menopausal gonadotropin
LH: luteinising hormone
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Ltz: letrozole
rFSH: recombinant follicle-stimulating hormone
WH A T ’ S N E W
Last assessed as up-to-date: 10 January 2017.
Date Event Description
11 October 2017 New search has been performed We have included 14 new trials in the update (Bastu
2016; Elnashar 2016; Fujimoto 2014; Galal 2012;
Ghosh Dastidar 2010; Jindal 2013; Lee 2012; Mohsen
2013; Mukherjee 2012; Nabati 2016; Pilehvari 2016;
Ragni 2012; Revelli 2014; Schimberni 2016).
We amended the review title to include other oral ovu-
lation induction medications such as letrozole, and have
evaluated interventions in the general in vitro fertilisa-
tion population and poor responders separately
11 October 2017 New citation required and conclusions have changed The scope of this review has been widened, and 14 new
studies added
C O N T R I B U T I O N S O F A U T H O R S
For the 2017 update:
MSK: data searching, selection of studies, data extraction, drafting of update, assessment of studies for inclusion, interpretation and
analysis of the data, and final editing of the review.
AM: input in selection of studies, and editing the final draft of the review.
SB: overall supervision, input in selection of studies, and editing the final draft of the review.
KYL: data searching, selection of studies, data extraction.
AG: data searching, selection of studies, data extraction, assessment of studies for inclusion, and contributed to final writing of the
manuscript.
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D E C L A R A T I O N S O F I N T E R E S T
MSK: no conflicts of interest to declare.
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S O U R C E S O F S U P P O R T
Internal sources
• Reproductive Medicine Unit, Christian Medical College, Vellore, India.
MSK is working in Christian Medical College, Vellore
• University of Aberdeen, UK.
AM and SB are currently working for the University of Aberdeen
• Mansoura University, Egypt.
AG is currently working for Mansoura University
External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Wehave changed the title of the review from ’Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation
inwomenundergoing in vitro fertilization’ to ’Oralmedications including clomiphene citrate or aromatase inhibitorswith gonadotropins
for controlled ovarian stimulation in women undergoing in vitro fertilisation’.
There has been a change of authors and contact author.
We have widened the scope of the current update by including other oral medications such as aromatase inhibitors for controlled
ovarian stimulation. This resulted in the following changes.
• Type of intervention: Clomiphene citrate with or without gonadotropins (original) and aromatase inhibitors with or without
gonadotropins (addition in update).
• Type of participants: We added the word ’fresh’ IVF. This was done to clearly indicate inclusion of only those women who had
oocyte retrieval and embryo transfer in the same cycle and not those women who had all embryos frozen and transferred in
subsequent cycles.
• Primary outcomes: We included ovarian hyperstimulation syndrome as a primary outcome (adverse) along with live birth.
• Risk of bias: We considered lack of blinding as low risk for performance and detection bias for the original review. However,
with ovarian hyperstimulation syndrome being added as a primary outcome for the general IVF population, we no longer considered
lack of blinding as low risk for this domain.
• Measures of treatment effect: We used risk ratio instead of odds ratio for dichotomous outcomes as it is more intuitive and easier
to understand. However, we used Peto odds ratio for dichotomous outcomes that were associated with low event rates.
• Data synthesis: In the original protocol, the main comparison group was clomiphene citrate with gonadotropins (with or
without gonadotropin-releasing hormone (GnRH) antagonist) versus gonadotropin in GnRH agonist protocol in IVF. However, with
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the advent of newer drugs and protocol, we changed this comparison. Also, due to wider use of oral medications in poor responders,
we evaluated the general population and poor responders in separate comparisons:
◦ clomiphene citrate or letrozole with or without gonadotropins (with or without midcycle GnRH antagonist) versus
gonadotropins (with GnRH agonist or midcycle antagonist protocols) in IVF and intracytoplasmic sperm injection cycles in the
general population;
◦ clomiphene citrate or letrozole with or without gonadotropins (with or without midcycle GnRH antagonist) versus
gonadotropins (with GnRH agonist or midcycle antagonist protocols) in IVF and intracytoplasmic sperm injection cycles in a
population of poor responders.
• Effects of interventions: Given the two different comparisons, we also presented the Effects of interventions separately for the
general population and poor responders.
• ’Summary of findings’ table: Given the two different comparisons, we also presented separate ’Summary of findings’ tables for
the general population and poor responders.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Clomiphene [∗administration &dosage]; DrugTherapy, Combination [methods]; Fertility Agents, Female [∗administration &dosage];
Fertilization in Vitro [∗methods]; Gonadotropin-Releasing Hormone [antagonists & inhibitors]; Gonadotropins [∗administration
& dosage]; Live Birth [epidemiology]; Nitriles [∗administration & dosage]; Oocyte Retrieval [statistics & numerical data]; Ovarian
Hyperstimulation Syndrome [chemically induced; epidemiology]; Ovulation Induction [∗methods]; Pregnancy Rate; Randomized
Controlled Trials as Topic; Sperm Injections, Intracytoplasmic; Triazoles [∗administration & dosage]
MeSH check words
Female; Humans; Pregnancy
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